BioGaia Protectis^®Family

10x probiotic chewable tablets with lemon flavor

The world’s 1st probiotic in chewable tablets (2000)

Unique probiotic, with probiotic and prebiotic properties at the same time…by its nature!

For gasrtrointestinal health in children and adults

Gastrointestinal disorders caused by Antibiotics/Diarrhoea/Constipation/Abdominal pain, Vomiting

FOR USE BY

Children from 3 years and adults

_________________________________________________

• It contains the world’s most studied probiotic strain in infants and children, one of the three most studied in adults
• Human strain, isolated in breast milk
• Natural habitat of our gastrointestinal tract from birth
• Unique parallel natural prebiotic action, due to its natural structure
• Clinically proven to colonize throughout the gastrointestinal tract
• Clinically proven per clinical benefit and age group
• Clinically proven, unique, natural, anti-pathogenic activity
• Safe for infants, children and adults, during pregnancy and breastfeeding and for diabetics
• Patented
• It contains no sugar, lactose, gluten, milk protein

• Scientifically documented in the prevention and treatment of functional gastrointestinaldisorders [(constipation/diarrhoea (regulates the bowel motility), reductions(increases gastric emptying rate)]
• Clinically proven in the prevention and treatment of gastrointestinal disordersassociated with taking antibiotics (diarrhoea, abdominal pain, flatulence etc.)
• Clinically proven to improve digestive health and function, where 80% of our immunesystem is located.
• Simple dosing regimen (1 tablet/day)

_________________________________________________

BioGaia Protectis^® probiotic chewable tablets are a simple, natural, safe and easy way to restore and maintain a healthy microbial balance in the gastrointestinal tract, as well as to improve digestive health and function.

BioGaia Protectis^® probiotic chewable tablets are a simple, natural, safe and easy way to restore and maintain a healthy microbial balance in the gastrointestinal tract, as well as to improve digestive health and function.

L. reuteri Protectis^® fully meets the requirements of WHO for probiotics. In an in vitro study comparing the viability of 35 different probiotic strains in a simulated human gastrointestinal tract over a period of five days, L. reuteri Protectis^® was shown to be one of the only three surviving strains. This was also confirmed in vivo, when ingestion from healthy humans led to significant colonisation of the stomach, duodenum and ileum.

L. reuteri Protectis^® fully meets the requirements of WHO for probiotics. In an in vitro study comparing the viability of 35 different probiotic strains in a simulated human gastrointestinal tract over a period of five days, L. reuteri Protectis^® was shown to be one of the only three surviving strains. This was also confirmed in vivo, when ingestion from healthy humans led to significant colonisation of the stomach, duodenum and ileum.

In addition, it is the only probiotic that produces the antimicrobial substance rheuterine against pathogenic microorganisms.

It contains the unique probiotic strain Limosilactobacillus reuteri Protectis^®
(former name Lactobacillus reuteri Protectis^®).

The unique natural substance Limosi –a high molecular weight exopolysaccharide biofilm (EPS)– surrounding the probiotic strain L. reuteri Protectis® also acts as a prebiotic for the symbiotic flora.

This biofilm: 

α) Protects the probiotic strain that surrounds it from

• other micro-organisms
• antibiotics
• toxic compounds
• osmotic stress

β) In human body

• It inhibits the adhesion of pathogens to the intestinal epithelium
• It supports the symbiotic microflora, acting as a prebiotic (food)
• It regulates the immune system by activating T-regulatory cells and increasing anti-inflammatory cytokines

USE

GASTROINTESTINAL DISORDERS CAUSED BY ANTIBIOTICS
(diarrhoea, abdominal pain, flatulence)

PREVENTION & TREATMENT

DOSAGE (prevention)

1 tablet once daily between antibiotics + for 3 days afterwards

DOSAGE (treatment)

1 tablet once after each antibiotics administration + for 3 days after

_________________________________________________

FUNCTIONAL ABDOMINAL PAIN
(i.e. when there are no pathological causes)

TREATMENT

DOSAGE

1 tablet daily for at least 1 month

_________________________________________________

CHRONIC CONSTIPATION
(i.e. symptoms that persist for >2 weeks)

TREATMENT

DOSAGE

1 tablet once daily

_________________________________________________

SUDDEN GASTROINTESTINAL DISORDERS
(diarrhoea, vomiting, flatulence, etc.)

TREATMENT

DOSAGE

2 tablets once daily

_________________________________________________

BioGaia AB

_________________________________________________

BioGaia AB is a Swedish biotechnology company and a global leader in probiotics, with a strong innovation profile, experience and expertise of over 30 years. To date, BioGaia AB holds more than 550 patents, a commercial presence in more than 100 countries and a physical presence in Europe, USA, China and Japan. BioGaia’s vision is to improve people’s health by offering probiotic products that are clinically documented and proven for safety and efficacy by clinical benefit and age group. Until now (2/2020) BioGaia AB has completed more than 217 clinical studies in infants, children and adults and has demonstrated the safety and efficacy of its probiotic products in various disorders.

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)

_________________________________________________

www.biogaia.gr
www.facebook.com/Biogaia.Greece
www.instagram.com/biogiaiagreece
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

BioGaia Prodentis^®

30x probiotic lozenges with apple flavor

The world’s 1st and most studied probiotic for oral health

Oral health for children and adults

Gingivitis / Caries / Periodontitis / Mycosis / Halitosis / Peri-implant mucositis / Peri-implantitis

FOR USE BY

Children from 4 years and adults

_________________________________________________

• The world’s 1st and most studied probiotic for oral health
• Specially formulated and clinically proven to prevent and treat problems that occur in the oral cavity
• It contains the world’s most studied probiotic strain in infants and children, one of the three    most studied in adults
• Unique combination of 2x probiotic strains with complementary properties
• Strains isolated in humans (of human origin)
• Unique parallel natural prebiotic action, due to their natural structure
• Clinically proven, unique, natural, dual, anti-pathogenic and anti-inflammatory, action
• Clinically studied combination
• Clinically proven per clinical benefit and age group
• Safe for children and adults, during pregnancy and breastfeeding
• Patented
• It contains no sugar, lactose, gluten, milk protein

• Scientifically documented for the prevention and treatment of problems of oral health.
• Clinically proven to reduce gingivitis levels.
  – 85% reduction of inflammation and bleeding in gingivitis patients just in two weeks..
• Clinically proven in chronic periodontitis.
  – 47% reduction of need for surgery in patients with chronic periodontitis after cleaning by technical means.
• Significant reduction of colonies of periodontal pathogens.
• Clinically proven in peri-implant mucositis or peri-implantitis after cleaning by technical means.
• Reduction of critical clinical parameters of plaque index (PI), gingival index (GI) and bleeding on probing (BOP).
• Reduction of pro-inflammatory cytokine levels (IL-1β, IL-6 and IL-8).
• Significant reduction of colonies of periodontal pathogens.
• Absolutely safe.

_________________________________________________

BioGaia Prodentis® probiotic lozenges are a simple, natural, safe and easy way to restore and maintain a healthy microbial balance in the oral cavity, to reduce the chances of tooth decay, to prevent or treat gingivitis and in general to reduce or treat soft tissue inflammation, which is responsible for many oral health problems.

They contain the clinically studied combination of two probiotic strains, L. reuteri Protectis^® and L. reuteri ATCC PTA 5465. L. reuteri Protectis^® (L. reuteri DSM 17938), BioGaia Sweden’s proprietary probiotic bacterium, originally isolated in breast milk, is the world’s most studied probiotic in infants and children and one of the three most studied in adults. Its safety and efficacy have been demonstrated in 217 clinical studies and 180 journal publications. (Last update: January 2020.)

L. reuteri Protectis^® and L. reuteri ATCC PTA 5465 fully meet the requirements of the WHO for probiotics. In an in vitro study comparing the viability of 35 different probiotic strains in a simulated human gastrointestinal tract over a period of five days, L. reuteri Protectis^® was shown to be one of the three surviving strains. This was also confirmed in vivo, when ingestion from healthy people resulted in significant colonisation of the stomach, duodenum and ileum.

L. reuteri Protectis^® colonizes the entire gastrointestinal tract, prevents the growth of harmful microorganisms, activates the immune system and improves gastrointestinal function.

In addition, it is the only probiotic that produces the antimicrobial substance reuterin against pathogenic microorganisms, so it has a unique anti-pathogenic effect, which is ideally complemented by L. reuteri ATCC PTA 5465, that offers a combination of its outstanding ability to provide its clinically proven anti-inflammatory action.

It contains the unique probiotic strains Limosilactobacillus reuteri Protectis^®
(former name Lactobacillus reuteri Protectis^®) + Limosilactobacillus reuteri ATCC PTA 5465 (former name Lactobacillus reuteri ATCC PTA 5465).

The unique natural substance Limosi –a high molecular weight exopolysaccharide (EPS) biofilm– surrounding the probiotic strains L. reuteri Protectis^® + L. reuteri ATCC PTA 6475 also acts as a prebiotic for the symbiotic flora.

This biofilm:

a) Protects the probiotic strain that surrounds it from

• other micro-organisms
• antibiotics
• toxic compounds
• osmotic stress

b) In human body  

• It inhibits the adhesion of pathogens to the intestinal epithelium.
• It supports the symbiotic microflora, acting as a prebiotic (food).
• It regulates the immune system by activating T-regulatory cells and  increasing anti-inflammatory cytokines.

USE – 4–17 YEARS

CARIES
(4–6  YEARS)

PREVENTION

DOSAGE

2 lozenges daily for 1 month

CARIES
(6–12  YEARS)

PREVENTION

DOSAGE

1 lozenge daily for 1 month

PRIMARY CARIES
(12–17 YEARS)

TREATMENT

DOSAGE

2 lozenges daily for 3 months

USE – FROM 18 YEARS

GINGIVITIS

PREVENTION & TREATMENT

DOSAGE

1 lozenge daily

_________________________________________________

PREGNANCY GINGIVITIS

TREATMENT

DOSAGE

1 lozenge daily for 4–7 weeks

_________________________________________________

PERIODONTITIS

TREATMENT

DOSAGE

2 lozenges daily for 3 months

(after antibiotic/antiseptic treatment)

_________________________________________________

PERI-IMPLANT MUCOSITIS/PERI-IMPLANTITIS

PREVENTION & TREATMENT

DOSAGE (prevention)

1 lozenge daily before implantation

DOSAGE (treatment)

2 lozenges daily for at least 1 month

(after antibiotic/antiseptic treatment)

_________________________________________________

MYCOSIS

TREATMENT

DOSAGE

2 lozenges daily

_________________________________________________

HALITOSIS
(BAD BREATH)

PREVENTION & TREATMENT

DOSAGE

1 lozenges daily

NOTE

For everyday use. Brush your teeth daily. BioGaia Prodentis^® should ideally be taken after brushing. If you are using an antiseptic/mouthwash, take BioGaia Prodentis^® half an hour after a mild antiseptic and one hour after a strong antiseptic.

_________________________________________________

BioGaia AB

_________________________________________________

BioGaia AB is a Swedish biotechnology company and a global leader in probiotics, with a strong innovation profile, experience and expertise of over 30 years. To date, BioGaia AB holds more than 550 patents, a commercial presence in more than 100 countries and a physical presence in Europe, USA, China and Japan. BioGaia’s vision is to improve people’s health by offering probiotic products that are clinically documented and proven for safety and efficacy by clinical benefit and age group. Until now (2/2020) BioGaia AB has completed more than 217 clinical studies in infants, children and adults and has demonstrated the safety and efficacy of its probiotic products in various disorders.

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)

_________________________________________________

www.biogaia.gr
www.facebook.com/Biogaia.Greece
www.instagram.com/biogaiagreece
ww.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

Imunoglukan P4H® 

30 capsules

The world’s 1st beta-glucan from the edible mushroom Pleurotus ostreatus

The world’s most studied beta-glucan in children

Side-chain beta-glucan with unique immunoregulatory properties

Clinically studied in children from 3 years and adults

Natural immunoregulatory action for children and adults

FOR USE BY

Children from 7 years and adults

The content of the capsule can be administered with water or food

_________________________________________________

• The 1st beta-glucan from the edible mushroom Pleurotus ostreatus
• Patented method of isolation and production of β-glucan
• Side-chain beta-glucan with unique immunomoregulatory properties
• The world’s most studied beta-glucan in children
• Clinically studied in children and adults
• Clinically proven to prevent and regulate immune against respiratory infections
• Clinically proven in the prevention and regulation of immune against recurrent respiratory infections
• Clinically proven in the prevention of respiratory infections of the lower respiratory tract
• Clinically studied for its antiallergic properties and respiratory infections  associated with allergies
• Clinically studied in adventitious infections associated with Crohn’s disease
• Clinically studied in the prevention of COPD exacerbations
• Clinically studied in supporting the immune system in athletes after intense exercise
• Does not contain gluten, sugar, alcohol or flavorings. It is suitable for diabetics and vegan

_________________________________________________

Immunoregulation in children and adults, which is based on the immunoregulatory properties of the natural functional ingredient Pleuran (IMG®). In a simplified description of the function of our immune system, we could say that an underactive immune system is vulnerable to infections etc., while when it is overactive, it can lead to allergies, chronic inflammation etc. Imunoglukan P4H® is a simple, natural, safe and clinically proven way of regulating the function and restoring balance to our immune system, with the benefits of restoring or maintaining it to normal levels.

The clinically proven Imunoglukan P4H® range of immunoregulatory products contains the clinically studied and patented natural functional ingredient IMG^® from Pleuran s.r.o. (parent company of Imunoglukan Ltd.).

IMG® is a biologically active polysaccharide, which was isolated for the 1st time from the edible mushroom Pleurotus ostreatus.

IMG® remains insoluble in the small intestine and is not absorbed. Its structure is unique (side-chain) and it is the one that gives its immunomodulatory properties, as the properties of beta-glucans depend entirely on their structure, which is different, depending on their origin.

The side-chain structure of IMG® is essential for its recognition by the immune-active cells of the Gut-associated lymphoid tissue (GALT) via specific receptors on Peyer’s plaques, such as dextin-1. In this way, natural immunity [involving monocytes, macrophages, natural killer (NK) cells and dendritic cells, as well as the associated peptides, cytokines, such as interferons and interleukins, that regulate the immune response] is initially activated. Subsequently, acquired immunity (involving B- and T-lymphocytes, as well as the associated cytokines, the lymphokines) is activated.

USE

PREVENTION
(Preparation, regulation and training of the immune system)

DOSAGE

1-2 capsules daily for at least 3 months

Suggested use for 6 months (October–March).

Ideally, it should be taken on an empty stomach in the evening before bedtime or in the morning

TREATMENT
(In acute phase – infections, stress, fatigue)

DOSAGE

2–3 capsules daily for at least 3–7 days

Ideally, it should be taken on an empty stomach in the evening before bedtime or in the morning

NOTE

Not to be taken/administered to transplant patients. Administration to immunocompromised persons may be made only with doctor’s advice and supervision

_________________________________________________

Pleuran s.r.o./Imunoglukan Ltd. (daughter company)

_________________________________________________

Pleuran s.r.o., a world leader in the research of beta-glucans for more than 25 years, was the first to isolate from the well-known edible mushroom Pleurotus ostreatus the beta-glucan, a polysaccharide-polymer of glucose with a structure that differentiates it from the beta-glucans of bacteria, cereals and moulds. The know-how of Pleuran s.r.o. led to the patented method of extracting the natural functional ingredient IMG®. The safety and efficacy of Imunoglukan P4H® have been proven to date* in 65 clinical studies in more than 10 research centers worldwide, it is already marketed in more than 30 countries and its properties make it a unique, natural, immunomodulatory product.

* Last update: January 2021

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)

_________________________________________________

www.imunoglukan.com/gr
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

Imunoglukan P4H® 

120ml syrup

The world’s 1st beta-glucan from the edible mushroom Pleurotus ostreatus

The world’s most studied beta-glucan in children

Side-chain beta-glucan with unique immunoregulatory properties

Clinically studied in children from 3 years and adults

Natural immunoregulatory action for children and adults

FOR USE BY

Children from 3 years and adults

_________________________________________________

• The 1st beta-glucan from the edible mushroom Pleurotus ostreatus
• Patented method of isolation and production of β-glucan
• Side-chain beta-glucan with unique immunomoregulatory properties
• The world’s most studied beta-glucan in children
• Clinically studied in children and adults
• Clinically proven to prevent and regulate immune against respiratory infections
• Clinically proven in the prevention and regulation of immune against  recurrent respiratory infections
• Clinically proven in the prevention of respiratory infections of the lower respiratory tract
• Clinically studied for its antiallergic properties and respiratory infections  associated with allergies
• Clinically studied in adventitious infections associated with Crohn’s disease
• Clinically studied in the prevention of COPD exacerbations
• Clinically studied in supporting the immune system in athletes after intense exercise
• Does not contain gluten, sugar, alcohol or flavorings. It is suitable for diabetics and vegan

_________________________________________________

Immunoregulation in children and adults, which is based on the immunoregulatory properties of the natural functional ingredient Pleuran (IMG^®). In a simplified description of the function of our immune system, we could say that an underactive immune system is vulnerable to infections etc., while when it is overactive, it can lead to allergies, chronic inflammation etc. Imunoglukan P4H^® is a simple, natural, safe and clinically proven way of regulating the function and restoring balance to our immune system, with the benefits of restoring or maintaining it to normal levels.

The clinically proven Imunoglukan P4H^® range of immunoregulatory products contains the clinically studied and patented natural functional ingredient IMG^® from Pleuran s.r.o. (parent company of Imunoglukan Ltd.).

IMG^® is a biologically active polysaccharide, which was isolated for the 1st time from the edible mushroom Pleurotus ostreatus.

IMG^® remains insoluble in the small intestine and is not absorbed. Its structure is unique (side-chain) and it is the one that gives its immunomodulatory properties, as the properties of beta-glucans depend entirely on their structure, which is different, depending on their origin. 

The side-chain structure of IMG^® is essential for its recognition by the immune-active cells of the Gut-associated lymphoid tissue (GALT) via specific receptors on Peyer’s plaques, such as dextin-1. In this way, natural immunity [involving monocytes, macrophages, natural killer (NK) cells and dendritic cells, as well as the associated peptides, cytokines, such as interferons and interleukins, that regulate the immune response] is initially activated. Subsequently, acquired immunity (involving B- and T-lymphocytes, as well as the associated cytokines, the lymphokines) is activated.

USE

The side-chain structure of IMG^® is essential for its recognition by the immune-active cells of the Gut-associated lymphoid tissue (GALT) via specific receptors on Peyer’s plaques, such as dextin-1. In this way, natural immunity [involving monocytes, macrophages, natural killer (NK) cells and dendritic cells, as well as the associated peptides, cytokines, such as interferons and interleukins, that regulate the immune response] is initially activated. Subsequently, acquired immunity (involving B- and T-lymphocytes, as well as the associated cytokines, the lymphokines) is activated.

PREVENTION
(Preparation, regulation and training of the immune system)

DOSAGE

1 ml per 5 kg body weight daily for at least 3 months

Suggested use for 6 months (October–March).

Ideally, it should be taken on an empty stomach in the evening before bedtime or in the morning

TREATMENT
(In acute phase – infections, stress, fatigue)

DOSAGE

2 ml per 5 kg body weight daily for at least 3–7 days

Ideally, it should be taken on an empty stomach in the evening before bedtime or in the morning

NOTE

Not to be taken/administered to transplant patients. Administration to immunocompromised persons may be made only with doctor’s advice and supervision

_________________________________________________

Pleuran s.r.o. / Imunoglukan Ltd. (daughter company)
_________________________________________________

Pleuran s.r.o., a world leader in the research of beta-glucans for more than 25 years, was the first to isolate from the well-known edible mushroom Pleurotus ostreatus the beta-glucan, a polysaccharide-polymer of glucose with a structure that differentiates it from the beta-glucans of bacteria, cereals and moulds. The know-how of Pleuran s.r.o. led to the patented method of extracting the natural functional ingredient IMG^®. The safety and efficacy of Imunoglukan P4H^® have been proven to date* in 65 clinical studies in more than 10 research centers worldwide, it is already marketed in more than 30 countries and its properties make it a unique, natural, immunomodulatory product.

* Last update: January 2021

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)

_________________________________________________

www.imunoglukan.com/gr
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

iovir^® PLUS nasal spray

20 ml with Carragelose^®, Kappa-Carrageenan + sorbitol

The world’s 1st spray with a broad spectrum against upper respiratory viruses + natural nasal decongestion

The only suitable from 1 year

The only with Carragelose^®

Treatment of upper respiratory viral infections

Relief from viral symptoms (nasal congestion)

Hydration (strengthening the natural defence mechanism)

FOR USE BY

Children from 1 year and adults

_________________________________________________

• The only with clinically proven safety and efficacy in children from 1 year
• Clinically proven safety and efficacy in adults
• The only with the natural ingredient Carragelose^®
• Developed on a patented technology platform, which targets more than 200 different viral
• strains
• Unique multiple mechanical action (protects, treats, relieves, hydrates)
• Not absorbed by the body
• Not addictive
• No risk of overdose
• Does not contain pharmaceutical ingredients and preservatives
• Suitable for long-term use
• Suitable for vulnerable groups
• Suitable for pregnant and breastfeeding women
• Suitable for diabetics
• Suitable for vegan
• Special filter – it remains sterile during use
• Patented
• It contains no sugar, lactose, gluten, ingredients of animal origin

• It can reduce the duration of the flu-like condition and the intensity of the symptoms of the common cold
• It may reduce the occurrence of new infections and the recurrence of symptoms associated with the common cold
• It decongests the stuffy nose, especially during the common cold, the flu, allergic or non- allergic rhinitis and sinusitis

_________________________________________________

In large clinical studies in children and adults it was proven that:

• Significantly reduces the viral load (clinical cases where more than one different viral  strain coexisted)
• It reduces the overall duration of viral illness
• It reduces the recurrence of viral illness (relapse)

_________________________________________________

The clinically proven iovir^® range of antiviral medical devices contains the clinically studied and patented natural functional ingredient Carragelose^® from the company Marinomed Austria, which is derived from red algae. The iovir^® range of medical devices offers a simple, natural, safe and easy way to prevent and adjunctively treat viral infections of the upper respiratory tract. iovir^® is designed and developed on a patented technology platform. The platform is used to develop therapies targeting more than 200 different respiratory viral strains responsible for the common cold and flu. Το iovir PLUS^® (nasal spray) contains the natural functional ingredients Carragelose^® and Kappa-carrageenan, which are derived from red algae. It has the unique property of creating a protective barrier to common cold viruses and traps upper respiratory viruses indiscriminately and broadly, preventing them from adhering to the mucosa and thus preventing their multiplication and spread. It also forms a moisturising protective membrane. Due to the action of Carragelose^® and Kappa-carrageenan ingredients, this membrane remains longer in the nasal mucosa and serves as a natural barrier against external influences. This physiological moisture membrane also supports the body’s natural defence mechanisms against common cold viruses. Finally, its natural hypertonic action causes the reduction of excess fluid from the nasal tissue, resulting in a reduction of swelling of the nasal mucosa, freeing up breathing.

USE (NATURAL PROPERTIES – MECHANICAL ACTION – VIRUS ENTRAPMENT)

TREATMENT

iovir^® PLUS has the ability to encapsulate viruses, forming a cocoon around them. This prevents the interaction of the viruses with the cells and inhibits the process of their multiplication and spread in the body.

RELIEF – HYDRATION

The protective natural moisture film provided by iovir^® PLUS, ^®, combined with the reduction of the cause that triggers inflammation in the nasal mucosa, offer immediate and prolonged relief from symptoms, such as nasal congestion, sore throat, feeling of dryness, etc.

NATURAL DECONGESTION

iovir^® PLUS contains sorbitol, which decongests the nose with a natural, osmotic mechanism and frees breathing.

DOSAGE (prevention/treatment)

1 spray per nostril many times daily or according to individual needs

_________________________________________________

Μarinomed Biotech AG
_________________________________________________

Marinomed Biotech AG is an Austrian biotechnology company. It was founded in 2006 as a spin-off company from the University of Vienna. It specializes in the development of innovative products in the field of infectious diseases based on its patented technology platforms. Marinomed has received several prestigious awards for its outstanding research and development activities. To date (5/2020), it holds 8 patents and has a commercial presence in more than 40 countries.

_________________________________________________

STERILE MEDICAL DEVICE

_________________________________________________

www.iovir.eu
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

iovir^® nasal spray

20 ml with Carragelose^®  and Kappa-Carrageenan

The world’s 1st topical spray against upper respiratory viruses

The only with Carragelose^®

The only suitable from 1 year

Protection from upper respiratory viruses

Treatment of upper respiratory viral infections

Relief from viral symptoms (runny nose/nasal itch)

Hydration (dryness of nasal mucosa/strengthening of natural defence mechanism)

FOR USE BY

Children from 1 year and adults

_________________________________________________

• The only with clinically proven safety and efficacy in children from 1 year
• Clinically proven safety and efficacy in adults
• The only with the natural ingredient Carragelose^®
• Developed on a patented technology platform, which targets more than 200 different viral
• strains
• Unique multiple mechanical action (protects, treats, relieves, hydrates)
• Not absorbed by the body
• Not addictive
• No risk of overdose
• Does not contain pharmaceutical ingredients and preservatives
• Suitable for long-term use
• Suitable for vulnerable groups
• Suitable for pregnant and breastfeeding women
• Suitable for diabetics
• Suitable for vegan
• Special filter – it remains sterile during use
• Patented
• It contains no sugar, lactose, gluten, ingredients of animal origin

• It may reduce the duration of the flu-like condition and the intensity of the symptoms of the common cold
• It may reduce the occurrence of new infections and the recurrence of symptoms associated with the common cold
• It is indicated for the prevention and supportive treatment of viral infections at the upper respiratory tract
• It may also be used for prophylactic and prolonged moistening of the nasal mucosa for prevention and supportive treatment of the symptoms related to dry or irritated nasal mucosa

_________________________________________________

In large clinical studies in children and adults it was proven that:

• Significantly reduces (>90%) the viral load (clinical cases where more than one different viral  strain coexisted)
• It is effective against >98% of upper respiratory viruses
• It reduces the overall duration of viral illness
• It reduces the recurrence of viral illness (relapse)

_________________________________________________

The clinically proven iovir^® range of antiviral medical devices contains the clinically studied and patented natural functional ingredient Carragelose^® from the company Marinomed Austria, which is derived from red algae. The iovir^® range of medical devices offers a simple, natural, safe and easy way to prevent and adjunctively treat viral infections of the upper respiratory tract. iovir^® is designed and developed on a patented technology platform. The platform is used to develop therapies targeting more than 200 different respiratory viral strains responsible for the common cold and flu. iovir^® (nasal spray) contains the natural functional ingredients Carragelose^® and Kappa-carrageenan, which are derived from red algae. It has the unique property of creating a protective barrier to common cold viruses and traps upper respiratory viruses indiscriminately and broadly, preventing them from adhering to the mucosa and thus preventing their multiplication and spread. It also forms a moisturising protective membrane. Due to the action of Carragelose^® and Kappa-carrageenan ingredients, this membrane remains longer in the nasal mucosa and serves as a natural barrier against external influences. This physiological moisture membrane also supports the body’s natural defence mechanisms against common cold viruses.

USE (NATURAL PROPERTIES – MECHANICAL ACTION – VIRUS ENTRAPMENT)

PROTECTION

iovir® creates a natural protective film of moisture in the mucous membrane of the nasal cavity, which acts against exogenous agents, preventing viruses from adhering to the cell membrane receptors and thus naturally supporting the body’s defence.

TREATMENT

iovir® has the ability to encapsulate viruses, forming a cocoon around them. This prevents the interaction of the viruses with the cells and inhibits the process of their multiplication and spread in the body.

RELIEF – HYDRATION

The protective natural moisture film provided by iovir^®, combined with the reduction of the cause that triggers inflammation in the nasal mucosa, offer immediate and prolonged relief from symptoms, such as runny nose, dryness, etc.

DOSAGE (prevention/treatment)

1 spray per nostril at least 3 times daily or according to individual needs

_________________________________________________

Μarinomed Biotech AG

_________________________________________________

Marinomed Biotech AG is an Austrian biotechnology company. It was founded in 2006 as a spin-off company from the University of Vienna. It specializes in the development of innovative products in the field of infectious diseases based on its patented technology platforms. Marinomed has received several prestigious awards for its outstanding research and development activities. To date (5/2020), it holds 8 patents and has a commercial presence in more than 40 countries.

_________________________________________________

STERILE MEDICAL DEVICE

________________________________________________

www.iovir.eu
ww.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

iovir^® throat spray

20 ml with Carragelose^® cherry flavour

The world’s 1st topical spray against upper respiratory viruses

The only with Carragelose^®

The only suitable from 1 year

Protection from upper respiratory viruses

Treatment of upper respiratory viral infections

Relief from viral symptoms (sore throat/cough)

Hydration (hoarseness/feeling of dryness of the oropharyngeal mucosa)

FOR USE BY

For children from 1 year and adults

_________________________________________________

• The only with clinically proven safety and efficacy in children from 1 year
• Clinically proven safety and efficacy in adults
• The only with the natural ingredient Carragelose^®
• Developed on a patented technology platform, which targets more than 200 different viral
• strains
• Unique multiple mechanical action (protects, treats, relieves, hydrates)
• Not absorbed by the body
• Not addictive
• No risk of overdose
• Does not contain pharmaceutical ingredients and preservatives
• Suitable for long-term use
• Suitable for vulnerable groups
• Suitable for pregnant and breastfeeding women
• Suitable for diabetics
• Suitable for vegan
• Special filter – it remains sterile during use
• Patented
• It contains no sugar, lactose, gluten, ingredients of animal origin

• For the prevention and adjunctive treatment of viral infections of the upper respiratory tract
• For the prevention and supportive treatment of all symptoms caused by
• dry and/or irritated mucous membranes of the mouth and throat
• For moistening the mouth and throat, for example in cases of coughing, hoarseness of voice or
• breathing in a dry environment

In large clinical studies in children and adults it was proven that:

• Significantly reduces (>90%) the viral load (clinical cases where more than one different viral
• strain coexisted)
• It is effective against >98% of upper respiratory viruses
• It reduces the overall duration of viral illness
• It reduces the recurrence of viral illness (relapse)

_________________________________________________

The clinically proven iovir^® range of antiviral medical devices contains the clinically studied and patented natural functional ingredient Carragelose^® from the company Marinomed Austria, which is derived from red algae. The iovir^® range of medical devices offers a simple, natural, safe and easy way to prevent and adjunctively treat viral infections of the upper respiratory tract. iovir^® is designed and developed on a patented technology platform. The platform is used to develop therapies targeting more than 200 different respiratory viral strains responsible for the common cold and flu. iovir^® (nasal spray) contains the natural functional ingredients Carragelose^® and Kappa-carrageenan, which are derived from red algae. It has the unique property of creating a protective barrier to common cold viruses and traps upper respiratory viruses indiscriminately and broadly, preventing them from adhering to the mucosa and thus preventing their multiplication and spread. It also forms a moisturising protective membrane. Due to the action of Carragelose^® and Kappa-carrageenan ingredients, this membrane remains longer in the nasal mucosa and serves as a natural barrier against external influences. This physiological moisture membrane also supports the body’s natural defence mechanisms against viruses of the upper respiratory tract.

USE (NATURAL PROPERTIES – MECHANICAL ACTION – VIRUS ENTRAPMENT)

PROTECTION

iovir® creates a natural protective film of moisture in the mucous membrane of the nasal cavity, which acts against exogenous agents, preventing viruses from adhering to the cell membrane receptors and thus naturally supporting the body’s defence.

TREATMENT

iovir® has the ability to encapsulate viruses, forming a cocoon around them. This prevents the interaction of the viruses with the cells and inhibits the process of their multiplication and spread in the body.

RELIEF – HYDRATION

The protective natural moisture film provided by iovir^®, combined with the reduction of the cause that triggers inflammation in the nasal mucosa, offer immediate and prolonged relief from symptoms, such as cough, sore throat, hoarseness, feeling of dryness, etc.

DOSAGE (prevention/treatment)

2–3 sprays per nostril at least 3 times daily or according to individual needs

_________________________________________________

Μarinomed Biotech AG

_________________________________________________

Marinomed Biotech AG is an Austrian biotechnology company. It was founded in 2006 as a spin-off company from the University of Vienna. It specializes in the development of innovative products in the field of infectious diseases based on its patented technology platforms. Marinomed has received several prestigious awards for its outstanding research and development activities. To date (5/2020), it holds 8 patents and has a commercial presence in more than 40 countries.

_________________________________________________

STERILE MEDICAL DEVICE

_________________________________________________

www.iovir.eu
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

Capricare^®  3 Powedered milk

400gr

The Original (1988) and No1 goat milk infant formula worldwide

Based on WHOLE goat milk

The only goat milk for infants evaluated by EFSA

FOR USE BY

Toddlers from 12 months and onwards
_________________________________________________

• The ORIGINAL goat milk infant formula (1988)
• The world’s No1 goat milk infant formula
• It is made from whole goat milk
• The only goat milk formula for infants that is clinically evaluated by the European Food Safety Agency (EFSA) for the proper development of a healthy infant
• The most studied goat milk infant formula
• Produced in the world’s most advanced, state of the art, manufacturing facility for production of goat milk infant formulas, designed to produce only infant formula exclusively from goat milk
• Unique vertical production (from breeding and milking to the final product)
• It complies with the European Directive for infant milk
• Enriched with long-chain polyunsaturated fatty acids (AA and DHA)

_________________________________________________

Milk powder for the nutritional coverage of infants after the 12th month.

It is prepared with whole goat milk as raw material instead of mixing ingredients, resulting in the mildest possible processing.

It complies with the European Infant Formula Directive and it is the only one clinically evaluated by the European Food Safety Agency (EFSA).

It is produced by the world leader in research, development and production of whole goat milk for infants, Dairy Goat Co-operative (DGC) New Zealand.

DGC’s unique and vertically integrated production process (breeding – milking – milk powder production – manufacturing of packaging materials – canning) ensures:

FASTEST PROCESS POSSIBLE

From milking the goats to milk powder within couple of days. It ensures the freshness and natural properties of whole goat milk.

LESS HARM TO THE RAW MATERIAL

The mildest heat treatment, with the least possible “disturbance” of the proteins and the lowest percentage of glycosylated compounds in the final product.

REDUCED RISK OF CONTAMINATION

No long-term storage of ingredients, large number of suppliers, transport and processing in other factories or countries.

QUALITY ASSURANCE

30 years of expertise. 100% focus on exclusive production of infant milk from whole goat milk. Total control of raw materials, packaging materials and all stages of production, ensuring the quality of the final product.

RESULT

The benefits of the unique natural properties of whole goat milk are retained in the final product:

• Better digestibility, due to its protein and lipid profile and milder processing
• Lower antigenicity
• Preservation of the liposphere membrane and the natural content of bioactive substances,  such as prebiotic oligosaccharides, nucleotides, amino acids, etc.

_________________________________________________

Dairy Goat Co-operative (DGC)

_________________________________________________

Dairy Goat Co-operative (DGC) Ltd., Nea Zealand, is the world leader in infant milk from goat milk. DGC is the inventor of infant milk from goat milk (1988). Throughout these 30 years, DGC has managed to keep a continuous evolution and to develop a highly sophisticated model of expertise around infant milk based on goat milk, that lead to the change of the European legislation for infant milks in 2012. DGC is a highly integrated co-operation, where every step in infant milk production, from farming and milking to infant milk in the can, is handled, controlled and completed in whole by DGC. The final product is produced and packaged in the world’s most sophisticated production facility for infant milk, designed to produce exclusively infant milk from whole goat milk.

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)

_________________________________________________

www.capricare.gr
www.facebook.com/Capricare.Greece
www.instagram.com/capricaregreece
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

BioGaia Gastrus® 

30x probiotic chewable tablets with mandarin flavor

Specially designed for problems related to the stomach

Unique probiotic, with probiotic and prebiotic properties at the same time…by its nature!

For stomach health of children and adults

Gastritis / Helicobacter Pylori / Stomach disorders

FOR USE BY

Children from 3 years and adults

_________________________________________________

• The world’s 1st probiotic, specifically designed for the eradication treatment of   Helicobacter pylori and for the treatment of stomach disorders
• Specially formulated and clinically proven to prevent and treat problems related to the stomach
• It contains the world’s most studied probiotic strain in infants and children, one of the three most studied in adults
• Unique combination of 2x probiotic strains with complementary properties
• Strains isolated in humans (of human origin)
• Unique parallel natural prebiotic action, due to their natural structure
• Clinically proven unique, natural, dual, anti-pathogenic and anti-inflammatory activity
• Clinically studied combination
• Clinically proven per clinical benefit
• Safe for children and adults, during pregnancy and breastfeeding and for diabetics
• Patented
• It contains no sugar, lactose, gluten, milk protein

• Clinically proven to reduce inflammation levels, such as in gastritis (reducing gastrin-17 and TNF-α).
• Clinically proven to reduce symptoms and side effects from the use of strong antibiotic therapy or taking antibiotics for a long period of time
• Clinically proven to reduce dysbiosis caused by taking antibiotics and proton pump inhibitors (PPIs)
• Clinically proven to increase the rate of gastric emptying
• Clinically proven to reduce adverse effects from eradication therapy of Helicobacter pylori, increasing its eradication rate and improving patient compliance to treatment
• Scientifically proven to improve digestive health and function
• Completely safe
• Simple dosing regimen (1 tablet/day)

_________________________________________________

BioGaia Gastrus^® probiotic chewable tablets are a simple, natural, safe and easy way to restore and maintain a healthy microbial balance in the gastrointestinal tract, to reduce inflammation and to treat functional gastrointestinal disorders caused during the eradication treatment of Helicobacter pylori.

BioGaia Gastrus^® probiotic chewable tablets are a simple, natural, safe and easy way to restore and maintain a healthy microbial balance in the gastrointestinal tract, to reduce inflammation and to treat functional gastrointestinal disorders caused during the eradication treatment of Helicobacter pylori.

L. reuteri Protectis^® and L. reuteri ATCC PTA 6475 fully meet the requirements set by the WHO for probiotics. In an in vitro study comparing the viability of 35 different probiotic strains in a simulated human gastrointestinal tract over a period of five days, L. reuteri Protectis^® was shown to be one of the three surviving strains. This was also confirmed in vivo, when ingestion from healthy people resulted in significant colonisation of the stomach, duodenum and ileum.

L. reuteri Protectis^® colonizes the entire gastrointestinal tract, prevents the growth of harmful microorganisms, activates the immune system and improves gastrointestinal function.

In addition, it is the only probiotic that produces the antimicrobial substance reuterin against pathogenic microorganisms, so it has a unique anti-pathogenic action, which is ideally complemented by L. reuteri ATCC PTA 6475, which offers a combination of its outstanding ability to survive in the hostile environment of the stomach for more than 3 hours and provide its clinically proven anti-inflammatory action.

It contains the unique probiotic strains Limosilactobacillus reuteri ATCC PTA 6475
(former name Lactobacillus reuteri Protectis® ) + Limosilactobacillus reuteri ATCC PTA 6475

The unique natural substance Limosi –a high molecular weight exopolysaccharide (EPS) biofilm– surrounding the probiotic strains L. reuteri Protectis^® + L. reuteri ATCC PTA 6475 also acts as a prebiotic for the symbiotic microflora.

This biofilm: 

a) Protects the probiotic strain that surrounds it from

• other micro-organisms
• antibiotics
• toxic compounds
• osmotic stress

b) In human body

• It inhibits the adhesion of pathogens to the intestinal epithelium.
• It supports the symbiotic microflora, acting as a prebiotic (food).
• It regulates the immune system by activating T-regulatory cells and increasing anti-inflammatory cytokines.

USE

GASTRITIS

PREVENTION & TREATMENT

DOSAGE

1 tablet daily

_________________________________________________

ERADICATION OF HELICOBACTER PYLORI & GASTRINTESTINAL ADVERSE EFFECTS FROM THE USE OF ANTIBIOTICS
(diarrhea, abdominal pain, flatulence)  

PREVENTION & TREATMENT

DOSAGE

1 tablet daily during the eradication treatment

1 tablet daily for 2–3 weeks after eradication treatment

_________________________________________________

STOMACH DISORDERS
(indigestion, bloating, abdominal pain, stomach pains, reductions, etc.)

TREATMENT

DOSAGE

1–2 tablets daily or based on individual needs

_________________________________________________

BioGaia AB
_________________________________________________

BioGaia AB is a Swedish biotechnology company and a global leader in probiotics, with a strong innovation profile, experience and expertise of over 30 years. To date, BioGaia AB holds more than 550 patents, a commercial presence in more than 100 countries and a physical presence in Europe, USA, China and Japan. BioGaia’s vision is to improve people’s health by offering probiotic products that are clinically documented and proven for safety and efficacy by clinical benefit and age group. Until now (2/2020) BioGaia AB has completed more than 217 clinical studies in infants, children and adults and has demonstrated the safety and efficacy of its probiotic products in various disorders.

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)

_________________________________________________

www.biogaia.gr
www.facebook.com/Biogaia.Greece
www.instagram.com/biogaiagreece
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

BioGaia Protectis® ORS Family (orange flavour)

7 sachets for probiotic Oral Rehydration Solution + zinc, with orange flavor

The world’s 1st hydration solution with probiotic and zinc (2009)

Unique probiotic, with probiotic and prebiotic properties at the same time…by its nature!

For intestinal health in children and adults

Gastrenteritis / Dehydration / Diarrhea / Vomiting

FOR USE BY

Infants from 1 year, children and adults

_________________________________________________

• Suitable from birth
• It contains the world’s most studied probiotic strain in infants and children, one of the three most studied in adults + zinc (antimicrobial activity)
• Human strain, isolated in breast milk
• Natural colonizer of our gastrointestinal tract from birth
• With unique, parallel, natural, prebiotic action, due to its natural structure
• Clinically proven to colonize the entire gastrointestinal tract
• Clinically proven per clinical benefit and age group
• Clinically proven, unique, natural, anti-pathogenic activity
• Safe for infants, children and adults, during pregnancy and breastfeeding
• Patented
• It contains no lactose, gluten, milk protein

_________________________________________________

It contains electrolytes, probiotic L. reuteri Protectis® and zinc. Available in a package of 7 sachets of 5.5 g. The contents of each sachet are dissolved in 250 ml of cool water, kept 3 hours out of the refrigerator or 6 hours in the refrigerator, and provides the following:

• Electrolytes and glucose
  [composition based on the most recent recommendations (WHO, UNICEF, ESPGHAN, ESPID)]*
• Probiotic strain L. reuteri Protectis^®
  [based on the official guidelines of ESPGHAN (2014) for the treatment of acute gastroenteritis in children]
• Zinc
  (based on WHO, UNICEF recommendations)
• Low osmolality (220 mOsm/kg)
  (based on WHO, ESPGHAN recommendations)

* WHO: World Health Organization
* ESPGHAN: European Society of Paediatric Gastroenterology, Hepatology and Nutrition
* ESPID: European Society for Paediatric Infectious Diseases

_________________________________________________

BioGaia Protectis^® ORS, probiotic oral hydration solution + zinc, is a simple, natural, safe and easy way to prevent and treat dehydration, e.g. caused by gastroenteritis, as well as to restore and maintain a healthy microbial balance in the gastrointestinal tract, in order to reduce the intensity and duration of symptoms associated with gastroenteritis.

It contains L. reuteri Protectis^® (L. reuteri DSM 17938), the patented probiotic bacterium of BioGaia Sweden. Originally isolated in breast milk, L. reuteri Protectis^® is the world’s most studied probiotic in infants and children and one of the three most studied in adults. Its safety and efficacy have been demonstrated in 217 clinical studies and 180 journal publications (last update: January 2020).

L. reuteri Protectis^® fully meets the requirements of WHO for probiotics. In an in vitro study comparing the viability of 35 different probiotic strains in a simulated human gastrointestinal tract over a period of five days, L. reuteri Protectis^® was shown to be one of the only three surviving strains. This was also confirmed in vivo, when ingestion from healthy humans led to significant colonisation of the stomach, duodenum and ileum.

In addition, it is the only probiotic that produces the antimicrobial substance rheuterine against pathogenic microorganisms, such as rotaviruses.

It contains the unique probiotic strain Limosilactobacillus reuteri Protectis^®
(former name Lactobacillus reuteri Protectis^®).

The unique natural substance Limosi –a high molecular weight exopolysaccharide biofilm (EPS)– surrounding the probiotic strain L. reuteri Protectis® also acts as a prebiotic for the symbiotic flora.

This biofilm:

a) Protects the probiotic strain that surrounds it from

• other micro-organisms
• antibiotics
• toxic compounds
• osmotic stress

b) In human body

• It inhibits the adhesion of pathogens to the intestinal epithelium.
• It supports the symbiotic microflora, acting as a prebiotic (food).
• It regulates the immune system by activating T-regulatory cells and
  increasing anti-inflammatory cytokines.

Its action has been shown in large published clinical studies to provide:

• 74% reduction in episodes of watery diarrhea from day 2 in hospitalized children
• 50% reduction in episodes of vomiting from day 2 in neonates and infants
• 45% additional reduction in the duration of diarrhoea with early intake of the probiotic

_________________________________________________

+ ZINC

_________________________________________________

According to studies and observations by the WHO and UNICEF:

• Zinc can reduce the duration and intensity of diarrhea.
• It can reduce the vomiting episodes.
• It does not affect the action of electrolytes.

_________________________________________________

ELECTROLYTE COMPOSITION

_________________________________________________

The electrolyte composition of BioGaia Protectis^® ORS is following the latest recommendations of WHO, UNICEF, ESPGHAN, ESPID.

According to the most recent studies and observations, the new formulation offers superior clinical benefits, and more specifically:

• It reduces the number of defecations by 20%.
• It reduces vomiting episodes by 30%.
• It reduces the need for emergency intravenous treatment by 33%.
• It does not increase the possibility of hyponatraemia.

USE

ELECTROLYTIC DISORDERS AND DEHYDRATATION CAUSED BY GASTRENTERITIS (mild and moderate diarrhoea and/or vomiting), EPHIDROSIS, FEVER OR STRENUOUS EXERCISE, ETC.

PREVENTION & TREATMENT

DOSAGE

1–4 sachets daily, depending on age and needs.

_________________________________________________

BioGaia AB
_________________________________________________

BioGaia AB is a Swedish biotechnology company and a global leader in probiotics, with a strong innovation profile, experience and expertise of over 30 years. To date, BioGaia AB holds more than 550 patents, a commercial presence in more than 100 countries and a physical presence in Europe, USA, China and Japan. BioGaia’s vision is to improve people’s health by offering probiotic products that are clinically documented and proven for safety and efficacy by clinical benefit and age group. Until now (2/2020) BioGaia AB has completed more than 217 clinical studies in infants, children and adults and has demonstrated the safety and efficacy of its probiotic products in various disorders.

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)

_________________________________________________

www.biogaia.gr
www.facebook.com/Biogaia.Greece
www.instagram.com/biogaiagreece
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

BioGaia Protectis® + D3 Family

30x probiotic chewable tablets with orange flavor

The world’s 1st probiotic in chewable tablets (2000)

Unique probiotic, with probiotic and prebiotic properties at the same time…by its nature!

For gasrtrointestinal health in children and adults

Gastrointestinal disorders caused by Antibiotics / Diarrhea / Constipation / Abdominal pain / Vomit
With Vitamin D3: Proper immune function / Bone and dental health / Prevention of rickets

FOR USE BY

Children from 3 years and adults

_________________________________________________

• It contains the world’s most studied probiotic strain in infants and children, one of the three most studied in adults
• Human strain, isolated in breast milk
• Natural habitat of our gastrointestinal tract from birth
• Unique parallel natural prebiotic action, due to its natural structure
• Clinically proven to colonize throughout the gastrointestinal tract
• Clinically proven per clinical benefit and age group
• Clinically proven, unique, natural anti-pathogenic activity
• Safe for infants, children and adults, during pregnancy and breastfeeding and for diabetics
• With vitamin D3, for proper immune function, bone and dental health and prevention of rickets in children and adults
• Patented
• It contains no sugar, lactose, gluten, milk protein

• Scientifically documented in the prevention and treatment of functional gastrointestinal  disorders
  [(constipation/diarrhoea (regulates the bowel motility), reductions (increases gastric emptying rate)]
• Clinically proven in the prevention and treatment of gastrointestinal disorders  associated with taking antibiotics (diarrhoea, abdominal pain, flatulence etc.)
• Clinically proven to improve digestive health and function, where 80% of our immune  system is located.
• Simple dosing regimen (1 tablet/day)

_________________________________________________

BioGaia Protectis^® probiotic chewable tablets are a simple, natural, safe and easy way to restore and maintain a healthy microbial balance in the gastrointestinal tract, as well as to improve digestive health and function.

BioGaia Protectis^® drops contain L. reuteri Protectis^® (L. reuteri DSM 17938), the patented probiotic bacterium of BioGaia Sweden. Originally isolated in breast milk, L. reuteri Protectis^® is the world’s most studied probiotic in infants and children and one of the three most studied in adults. Its safety and efficacy have been demonstrated in 217 clinical studies and 180 journal publications (last update: January 2020).

L. reuteri Protectis^® fully meets the requirements of WHO for probiotics. In an in vitro study comparing the viability of 35 different probiotic strains in a simulated human gastrointestinal tract over a period of five days, L. reuteri Protectis^® was shown to be one of the only three surviving strains. This was also confirmed in vivo, when ingestion from healthy humans led to significant colonisation of the stomach, duodenum and ileum.

L. reuteri Protectis^® colonizes the entire gastrointestinal tract, prevents the growth of harmful microorganisms, activates the immune system and improves gastrointestinal function.

In addition, it is the only probiotic that produces the antimicrobial substance rheuterine against pathogenic microorganisms.

+VITAMIN D

The recommended dosage of 1 tablet per day provides 800 IU of vitamin D according to the European Food Safety Authority (EFSA) for children and adults. A daily intake of 800IU of vitamin D is recommended to meet dietary vitamin D needs for proper bone development and dental health in children and the prevention of rickets. Meeting these needs is often difficult due to the dependence of intake on each person’s diet, sun exposure, skin color and underlying diseases.

L. reuteri Protectis® has been shown to improve the body’s absorption of vitamin D and works synergistically to strengthen the immune system. It contains the unique probiotic strain Limosilactobacillus reuteri Protectis^®
(former name Lactobacillus reuteri Protectis^®).

The unique natural substance Limosi –a high molecular weight exopolysaccharide biofilm (EPS)– surrounding the probiotic strain L. reuteri Protectis® also acts as a prebiotic for the symbiotic flora.

This biofilm:

a) Protects the probiotic strain that surrounds it from

• other micro-organisms
• antibiotics
• toxic compounds
• osmotic stress

b) In human body

• It inhibits the adhesion of pathogens to the intestinal epithelium
• It supports the symbiotic microflora, acting as a prebiotic (food)
• It regulates the immune system by activating T-regulatory cells and increasing anti-inflammatory cytokines

USE

GASTROINTESTINAL DISORDERS CAUSED BY ANTIBIOTICS
(diarrhoea, abdominal pain, flatulence)

PREVENTION & TREATMENT

DOSAGE (prevention)

1 tablet once daily between antibiotics + for 3 days afterwards

DOSAGE (treatment)

1 tablet once after each antibiotics administration + for 3 days after

_________________________________________________

FUNCTIONAL ABDOMINAL PAIN
(i.e. when there are no pathological causes)

TREATMENT

DOSAGE

1 tablet daily for at least 1 month

_________________________________________________

CHRONIC CONSTIPATION
(i.e. symptoms that persist for >2 weeks)

TREATMENT

DOSAGE

1 tablet once daily

_________________________________________________

SUDDEN GASTROINTESTINAL DISORDERS
(diarrhoea, vomiting, flatulence, etc.)

TREATMENT

DOSAGE

2 tablets once daily

_________________________________________________

BioGaia AB
_________________________________________________

BioGaia AB is a Swedish biotechnology company and a global leader in probiotics, with a strong innovation profile, experience and expertise of over 30 years. To date, BioGaia AB holds more than 550 patents, a commercial presence in more than 100 countries and a physical presence in Europe, USA, China and Japan. BioGaia’s vision is to improve people’s health by offering probiotic products that are clinically documented and proven for safety and efficacy by clinical benefit and age group. Until now (2/2020) BioGaia AB has completed more than 217 clinical studies in infants, children and adults and has demonstrated the safety and efficacy of its probiotic products in various disorders.

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)

_________________________________________________

www.biogaia.gr
www.facebook.com/Biogaia.Greece
www.instagram.com/biogaiagreece
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

BioGaia Protectis^® Family

60x probiotic chewable tablets with lemon flavor

The world’s 1st probiotic in chewable tablets (2000)

Unique probiotic, with probiotic and prebiotic properties at the same time…by its nature!

For gasrtrointestinal health in children and adults

Gastrointestinal disorders caused by Antibiotics / Diarrhea / Constipation / Abdominal pain / Vomiting

FOR USE BY

Children from 3 years and adults

_________________________________________________

• It contains the world’s most studied probiotic strain in infants and children, one of the three most studied in adults
• Human strain, isolated in breast milk
• Natural habitat of our gastrointestinal tract from birth
• Unique parallel natural prebiotic action, due to its natural structure
• Clinically proven to colonize throughout the gastrointestinal tract
• Clinically proven per clinical benefit and age group
• Clinically proven, unique, natural, anti-pathogenic activity
• Safe for infants, children and adults, during pregnancy and breastfeeding and for diabetics
• Patented
• It contains no sugar, lactose, gluten, milk protein

• Scientifically documented in the prevention and treatment of functional gastrointestinal disorders
  [(constipation/diarrhoea (regulates the bowel motility), reductions  (increases gastric emptying rate)]
• Clinically proven in the prevention and treatment of gastrointestinal disorders  associated with taking antibiotics (diarrhoea, abdominal pain, flatulence etc.)
• Clinically proven to improve digestive health and function, where 80% of our immune system is located.
• Simple dosing regimen (1 tablet/day)

_________________________________________________

BioGaia Protectis^® probiotic chewable tablets are a simple, natural, safe and easy way to restore and maintain a healthy microbial balance in the gastrointestinal tract, as well as to improve digestive health and function.

BioGaia Protectis^® drops contain L. reuteri Protectis^® (L. reuteri DSM 17938), the patented probiotic bacterium of BioGaia Sweden. Originally isolated in breast milk, L. reuteri Protectis^® is the world’s most studied probiotic in infants and children and one of the three most studied in adults. Its safety and efficacy have been demonstrated in 217 clinical studies and 180 journal publications (last update: January 2020).

L. reuteri Protectis^® fully meets the requirements of WHO for probiotics. In an in vitro study comparing the viability of 35 different probiotic strains in a simulated human gastrointestinal tract over a period of five days, L. reuteri Protectis^® was shown to be one of the only three surviving strains. This was also confirmed in vivo, when ingestion from healthy humans led to significant colonisation of the stomach, duodenum and ileum.

L. reuteri Protectis^® colonizes the entire gastrointestinal tract, prevents the growth of harmful microorganisms, activates the immune system and improves gastrointestinal function.

In addition, it is the only probiotic that produces the antimicrobial substance rheuterine against pathogenic microorganisms.

It contains the unique probiotic strain Limosilactobacillus reuteri Protectis^®
(former name Lactobacillus reuteri Protectis^®).

The unique natural substance Limosi –a high molecular weight exopolysaccharide biofilm (EPS)– surrounding the probiotic strain L. reuteri Protectis® also acts as a prebiotic for the symbiotic flora.

This biofilm:

a) Protects the probiotic strain that surrounds it from

• other micro-organisms
• antibiotics
• toxic compounds
• osmotic stress

b) In human body 

• It inhibits the adhesion of pathogens to the intestinal epithelium
• It supports the symbiotic microflora, acting as a prebiotic (food)
• It regulates the immune system by activating T-regulatory cells and increasing anti-inflammatory cytokines

USE

GASTROINTESTINAL DISORDERS CAUSED BY ANTIBIOTICS
(diarrhoea, abdominal pain, flatulence)

PREVENTION & TREATMENT

DOSAGE (prevention)

1 tablet once daily between antibiotics + for 3 days afterwards

DOSAGE (treatment)

1 tablet once after each antibiotics administration + for 3 days after

_________________________________________________

FUNCTIONAL ABDOMINAL PAIN
(i.e. when there are no pathological causes)

TREATMENT

DOSAGE

1 tablet daily for at least 1 month

_________________________________________________

CHRONIC CONSTIPATION
(i.e. symptoms that persist for >2 weeks)

TREATMENT

DOSAGE

1 tablet once daily

_________________________________________________

SUDDEN GASTROINTESTINAL DISORDERS
(diarrhoea, vomiting, flatulence, etc.)

TREATMENT

DOSAGE

2 tablets once daily

_________________________________________________

BioGaia AB
_________________________________________________

BioGaia AB is a Swedish biotechnology company and a global leader in probiotics, with a strong innovation profile, experience and expertise of over 30 years. To date, BioGaia AB holds more than 550 patents, a commercial presence in more than 100 countries and a physical presence in Europe, USA, China and Japan. BioGaia’s vision is to improve people’s health by offering probiotic products that are clinically documented and proven for safety and efficacy by clinical benefit and age group. Until now (2/2020) BioGaia AB has completed more than 217 clinical studies in infants, children and adults and has demonstrated the safety and efficacy of its probiotic products in various disorders.

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)

_________________________________________________

www.biogaia.gr
www.facebook.com/Biogaia.Greece
www.instagram.com/biogiaiagreece
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

BioGaia Protectis^® Family

30x probiotic chewable tablets with lemon flavor

The world’s 1st probiotic in chewable tablets (2000)

Unique probiotic, with probiotic and prebiotic properties at the same time…by its nature!

For gasrtrointestinal health in children and adults

Gastrointestinal disorders caused by Antibiotics / Diarrhea / Constipation / Abdominal pain / Vomit

FOR USE BY

Children from 3 years and adults

_________________________________________________

• It contains the world’s most studied probiotic strain in infants and children, one of the three most studied in adults
• Human strain, isolated in breast milk
• Natural habitat of our gastrointestinal tract from birth
• Unique parallel natural prebiotic action, due to its natural structure
• Clinically proven to colonize throughout the gastrointestinal tract
• Clinically proven per clinical benefit and age group
• Clinically proven, unique, natural anti-pathogenic activity
• Safe for infants, children and adults, during pregnancy and breastfeeding and for diabetics
• Patented
• It contains no sugar, lactose, gluten, milk protein

• Scientifically documented in the prevention and treatment of functional gastrointestinaldisorders
  [(constipation/diarrhoea (regulates the bowel motility), reductions(increases gastric emptying rate)]
• Clinically proven in the prevention and treatment of gastrointestinal disordersassociated with taking antibiotics (diarrhoea, abdominal pain, flatulence etc.)
• Clinically proven to improve digestive health and function, where 80% of our immunesystem is located.
• Simple dosing regimen (1 tablet/day)

_________________________________________________

BioGaia Protectis^® probiotic chewable tablets are a simple, natural, safe and easy way to restore and maintain a healthy microbial balance in the gastrointestinal tract, as well as to improve digestive health and function.

BioGaia Protectis^® drops contain L. reuteri Protectis^® (L. reuteri DSM 17938), the patented probiotic bacterium of BioGaia Sweden. Originally isolated in breast milk, L. reuteri Protectis^® is the world’s most studied probiotic in infants and children and one of the three most studied in adults. Its safety and efficacy have been demonstrated in 217 clinical studies and 180 journal publications (last update: January 2020).

L. reuteri Protectis^® fully meets the requirements of WHO for probiotics. In an in vitro study comparing the viability of 35 different probiotic strains in a simulated human gastrointestinal tract over a period of five days, L. reuteri Protectis^® was shown to be one of the only three surviving strains. This was also confirmed in vivo, when ingestion from healthy humans led to significant colonisation of the stomach, duodenum and ileum.

L. reuteri Protectis^® colonizes the entire gastrointestinal tract, prevents the growth of harmful microorganisms, activates the immune system and improves gastrointestinal function.

In addition, it is the only probiotic that produces the antimicrobial substance rheuterine against pathogenic microorganisms.

It contains the unique probiotic strain Limosilactobacillus reuteri Protectis^®
(former name Lactobacillus reuteri Protectis^®).

The unique natural substance Limosi –a high molecular weight exopolysaccharide biofilm (EPS)– surrounding the probiotic strain L. reuteri Protectis® also acts as a prebiotic for the symbiotic flora.

This biofilm:

α) Protects the probiotic strain that surrounds it from

• other micro-organisms
• antibiotics
• toxic compounds
• osmotic stress

β) In human body

• It inhibits the adhesion of pathogens to the intestinal epithelium
• It supports the symbiotic microflora, acting as a prebiotic (food)
• It regulates the immune system by activating T-regulatory cells and  increasing anti-inflammatory cytokines

USE

GASTROINTESTINAL DISORDERS CAUSED BY ANTIBIOTICS
(diarrhoea, abdominal pain, flatulence)

PREVENTION & TREATMENT

DOSAGE (prevention)

1 tablet once daily between antibiotics + for 3 days afterwards

DOSAGE (treatment)

1 tablet once after each antibiotics administration + for 3 days after

_________________________________________________

FUNCTIONAL ABDOMINAL PAIN
(i.e. when there are no pathological causes)

TREATMENT

DOSAGE

1 tablet daily for at least 1 month

_________________________________________________

CHRONIC CONSTIPATION
(i.e. symptoms that persist for >2 weeks)

TREATMENT

DOSAGE

1 tablet once daily

_________________________________________________

SUDDEN GASTROINTESTINAL DISORDERS
(diarrhoea, vomiting, flatulence, etc.)

TREATMENT

DOSAGE

2 tablets once daily

_________________________________________________

BioGaia AB
_________________________________________________

BioGaia AB is a Swedish biotechnology company and a global leader in probiotics, with a strong innovation profile, experience and expertise of over 30 years. To date, BioGaia AB holds more than 550 patents, a commercial presence in more than 100 countries and a physical presence in Europe, USA, China and Japan. BioGaia’s vision is to improve people’s health by offering probiotic products that are clinically documented and proven for safety and efficacy by clinical benefit and age group. Until now (2/2020) BioGaia AB has completed more than 217 clinical studies in infants, children and adults and has demonstrated the safety and efficacy of its probiotic products in various disorders.

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)

_________________________________________________

www.biogaia.gr
www.facebook.com/Biogaia.Greece
www.instagram.com/biogiaiagreece
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

Lacteeze® chewable tablets

100x chewable tablets with natural strawberry flavor

Natural lactase enzyme

For the breakdown of lactose before the consumption of solid and liquid foods and products containing lactose [e.g. yoghurt, cheese, biscuits etc. or fresh milk, powdered milk, condensed milk, breast milk, formula, chocolate milk, etc.]

FOR USE BY

Newborn infants (dissolved in milk, water, etc.), children and adults

_________________________________________________

• Not a drug – it is a natural enzyme that under normal conditions is prodcuced in the digestive tract
• It breaks down the lactose in milk, it can be consumed without the occurrence of the unwanted symptoms caused by lactose intolerance
• Safe from birth
• Safe during pregnancy and breastfeeding
• Does not contain preservatives, artificial colours or flavorings
• Clinically proven action
• Allows children and adults to continue drinking milk (e.g. fresh, extensively pasteurized, chocolate flavored etc.)
• Enables mothers to continue breastfeeding, even if their baby has lactose intolerance
• Does not contain gluten, dairy elements

_________________________________________________

LACTASE ENZYME

_________________________________________________

The enzyme lactase is naturally produced in the small intestine and it is responsible for breaking down lactose in foods containing it (dairy and products containing lactose) to enable its absorption by our body. As we grow older, the body’s production of lactase gradually decreases. The inhibition of its production also occurs after gastroenteritis, where the intestine is “injured” and it takes 1–2 weeks to return to its normal function in terms of enzyme production. Therefore, after gastroenteritis, Lacteeze^® can help to continue consuming milk without problems.

Lacteeze^® chewable tablets are a simple, natural, safe and easy way for our body to obtain the natural enzyme lactase, which is deficient when we are lactose intolerant. It has been estimated that in Greece ≈30% of children and ≈70% of adults suffer from lactose intolerance. Most often, symptoms are attributed to other causes, due to possible misdiagnosis. If you frequently suffer from bloating, gas or flatulence, abdominal pain or watery stools, you may have lactose intolerance. Lacteeze^® restores nutritional completeness and taste satisfaction to those who avoid lactose-containing foods.

NOTE

Lacteeze^® is not absorbed. Whatever amount does not interact with the lactose consumed through dairy products is eliminated from the organism naturally. Lacteeze^® tablets should be taken every time you consume dairy products, just before consumption. Repeat the dose if dairy consumption continues after one hour. Adjust according to your needs. Take up to 3 times a day and no more than 12 tablets in total.

USE

BREASTFEEDING

Dissolve 1/4 of the tablet in a small amount of water or breast milk that you have extracted naturally or with a breast pump. Mix and give the mixture to the baby before you start breastfeeding

INFANT MILK

Dissolve 1/4 of the tablet in a small amount of water, milk that you have prepared. Mix and give the mixture to the baby before you start feeding

CHILDREN 2–3 YEARS

Do not give the tablet to children to swallow, there is a risk of choking. Dissolve 1 tablet in water or food just before eating dairy products

CHILDREN 4–12 YEARS

Chew 1 tablet just before consuming dairy products

ADULTS

Chew or swallow 1-3 tablets just before eating dairy products

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)

_________________________________________________

www.lacteeze.eu
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

Lacteeze® drops

7 ml drops

Natural lactase enzyme

To break down the lactose contained in ≈30 litres of milk

FOR USE BY

Newborn infants, children and adults

_________________________________________________

• Not a drug – it is a natural enzyme that under normal conditions is prodcuced in the digestive tract
• It breaks down the lactose in milk, it can be consumed without the occurrence of the unwanted symptoms caused by lactose intolerance
• Safe from birth
• Safe during pregnancy and breastfeeding
• Does not contain preservatives, artificial colours or flavorings
• Clinically proven action
• Allows children and adults to continue drinking milk (e.g. fresh, extensively pasteurized, chocolate flavored etc.)
• Enables mothers to continue breastfeeding, even if their baby has lactose intolerance
• Does not contain gluten, yeast, dairy elements

_________________________________________________

LACTASE ENZYME

_________________________________________________

The enzyme lactase is naturally produced in the small intestine and it is responsible for breaking down lactose in foods containing it (dairy and products containing lactose) to enable its absorption by our body. As we grow older, the body’s production of lactase gradually decreases. The inhibition of its production also occurs after gastroenteritis, where the intestine is “injured” and it takes 1–2 weeks to return to its normal function in terms of enzyme production. Therefore, after gastroenteritis, Lacteeze^® can help to continue consuming milk without problems.

Lacteeze® drops are a simple, natural, safe and easy way to break down lactose, which is found in dairy products that are in liquid form [e.g. fresh milk, milk powder, condensed milk, breast milk, infant milk powder (formula), chocolate milk and any other liquid milk product]. The drops must be added to the liquid containing lactose in order to break it down. It has been estimated that in Greece ≈30% of children and ≈70% of adults suffer from lactose intolerance. Most often, symptoms are attributed to other causes, due to possible misdiagnosis. If you frequently suffer from bloating, gas or flatulence, abdominal pain or watery stools, you may have lactose intolerance. Lacteeze^® restores nutritional completeness and taste satisfaction to those who avoid lactose-containing foods.

NOTE

Lacteeze® is not absorbed. The amount that does not interact with the lactose consumed through dairy products is eliminated from the organism naturally. Milk, to which Lacteeze^® has been added, has a slightly sweeter taste. This is natural, as it is due to the breakdown of lactose. The nutritional value of the milk is not affected.

USE

IN MILK
(fresh, pasteurized, chocolate, etc.)

Step 1  

Add 5 drops of Lacteeze^® per litre of milk

Step 2  

Mix well and refrigerate the milk for 24 hours before consuming it (70–80% of the lactose is broken down). If you want to break down more lactose, you can increase the number of drops or leave the milk in the fridge for longer

BREASTFEEDING

Step 1  

Extract 1 teaspoon of breast milk into a sterile container

Step 2  

Add 4 drops of Lacteeze^® to the container

Step 3

Give the mixture to the baby and continue breastfeeding normally (≈40% of the lactose is broken down). If you want to break down more lactose, you can increase the number of drops

IN BREAST MILK EXTRACTED WITH BREAST PUMP

Step 1 

Add 4 drops of Lacteeze^® per 50 ml of warm (not hot) breast milk extracted with a breast pump

Step 2

Shake well and wait 30 minutes before drinking. Do not refrigerate it. This will break down about 90% of the lactose. Alternatively, you can add 2 drops of Lacteeze^® per 50 ml of warm breast milk. Shake well and wait 5 minutes before refrigerating it for 4 hours before consuming it. This will break down about 80% of the lactose.

IN INFANT FORMULA

Step 1 

Add 4 drops of Lacteeze^® per 50 ml of warm baby milk (not hot, about 30–40°C)

Step 2

Shake well and wait for 30 minutes before consuming. Do not refrigerate it. This will break down about 80% of the lactose. Alternatively, you can add 2 drops of Lacteeze^® per 50 ml of warm baby milk. Shake well and wait 5 minutes before refrigerating it for 4 hours before consuming it. This will break down about 60% of the lactose

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)

_________________________________________________

www.lacteeze.eu
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

BioGaia Protectis® ORS Child

7 sachets of probiotic hydration/electrolyte solution + zinc

The world’s 1st hydration solution with probiotic and zinc (2009)

Unique probiotic, with probiotic and prebiotic properties at the same time…by its nature!

For intestinal health in children and adults

Gastrenteritis / Dehydration / Diarrhea / Vomiting

FOR USE BY

Infants from birth, young children and adults

_________________________________________________

• Suitable from birth
• It contains the world’s most studied probiotic strain in infants and children, one of the three most studied in adults + zinc (antimicrobial activity)
• Human strain, isolated in breast milk
• Natural colonizer of our gastrointestinal tract from birth
• With unique, parallel, natural, prebiotic action, due to its natural structure
• Clinically proven to colonize the entire gastrointestinal tract
• Clinically proven per clinical benefit and age group
• Clinically proven, unique, natural, anti-pathogenic activity
• Safe for infants, children and adults, during pregnancy and breastfeeding
• Patented
• It contains no lactose, gluten, milk protein.

_________________________________________________

It contains electrolytes, probiotic L. reuteri Protectis® and zinc. Available in a package of 7 sachets of 5.5 g. The contents of each sachet are dissolved in 250 ml of cool water, kept 3 hours out of the refrigerator or 6 hours in the refrigerator, and provides the following:

• Electrolytes and glucose
  [composition based on the most recent recommendations (WHO, UNICEF, ESPGHAN,  ESPID)]*
• Probiotic strain L. reuteri Protectis^®
   [based on the official guidelines of ESPGHAN (2014) for the treatment of acute   gastroenteritis in children]
• Zinc
  (based on WHO, UNICEF recommendations)
• Low osmolality (220 mOsm/kg)
  (based on WHO, ESPGHAN recommendations)

* WHO: World Health Organization
* ESPGHAN: European Society of Paediatric Gastroenterology, Hepatology and Nutrition
* ESPID: European Society for Paediatric Infectious Diseases

_________________________________________________

BioGaia Protectis^® ORS, probiotic oral hydration solution + zinc, is a simple, natural, safe and easy way to prevent and treat dehydration, e.g. caused by gastroenteritis, as well as to restore and maintain a healthy microbial balance in the gastrointestinal tract, in order to reduce the intensity and duration of symptoms associated with gastroenteritis.

BioGaia Protectis^® ORS, probiotic oral hydration solution + zinc, is a simple, natural, safe and easy way to prevent and treat dehydration, e.g. caused by gastroenteritis, as well as to restore and maintain a healthy microbial balance in the gastrointestinal tract, in order to reduce the intensity and duration of symptoms associated with gastroenteritis.

L. reuteri Protectis^® fully meets the requirements of WHO for probiotics. In an in vitro study comparing the viability of 35 different probiotic strains in a simulated human gastrointestinal tract over a period of five days, L. reuteri Protectis^® was shown to be one of the only three surviving strains. This was also confirmed in vivo, when ingestion from healthy humans led to significant colonisation of the stomach, duodenum and ileum.

In addition, it is the only probiotic that produces the antimicrobial substance rheuterine against pathogenic microorganisms, such as rotaviruses.

It contains the unique probiotic strain Limosilactobacillus reuteri Protectis^®
(former name Lactobacillus reuteri Protectis^®).

The unique natural substance Limosi –a high molecular weight exopolysaccharide biofilm (EPS)– surrounding the probiotic strain L. reuteri Protectis® also acts as a prebiotic for the symbiotic flora.

This biofilm:

a) Protects the probiotic strain that surrounds it from

• other micro-organisms
• antibiotics
• toxic compounds
• osmotic stress

b) In human body

• It inhibits the adhesion of pathogens to the intestinal epithelium.
• It supports the symbiotic microflora, acting as a prebiotic (food).
• It regulates the immune system by activating T-regulatory cells and increasing anti-inflammatory cytokines.

Its action has been shown in large published clinical studies to provide:

• 74% reduction in episodes of watery diarrhea from day 2 in hospitalized children
• 50% reduction in episodes of vomiting from day 2 in neonates and infants
• 45% additional reduction in the duration of diarrhoea with early intake of the probiotic

_________________________________________________

+ ZINC

_________________________________________________

According to studies and observations by the WHO and UNICEF:

• Zinc can reduce the duration and intensity of diarrhea.
• It can reduce the vomiting episodes.
• It does not affect the action of electrolytes.

_________________________________________________

ELECTROLYTE COMPOSITION

_________________________________________________

The electrolyte composition of BioGaia Protectis^® ORS is following the latest recommendations of WHO, UNICEF, ESPGHAN, ESPID.

According to the most recent studies and observations, the new formulation offers superior clinical benefits, and more specifically:

• It reduces the number of defecations by 20%.
• It reduces vomiting episodes by 30%.
• It reduces the need for emergency intravenous treatment by 33%.
• It does not increase the possibility of hyponatraemia.

USE

ELECTROLYTIC DISORDERS AND DEHYDRATATION CAUSED BY GASTRENTERITIS (mild and moderate diarrhoea and/or vomiting), EPHIDROSIS, FEVER OR STRENUOUS EXERCISE, ETC.

PREVENTION & TREATMENT

DOSAGE

1–4 sachets daily, depending on age and needs.

_________________________________________________

BioGaia AB
_________________________________________________

BioGaia AB is a Swedish biotechnology company and a global leader in probiotics, with a strong innovation profile, experience and expertise of over 30 years. To date, BioGaia AB holds more than 550 patents, a commercial presence in more than 100 countries and a physical presence in Europe, USA, China and Japan. BioGaia’s vision is to improve people’s health by offering probiotic products that are clinically documented and proven for safety and efficacy by clinical benefit and age group. Until now (2/2020) BioGaia AB has completed more than 217 clinical studies in infants, children and adults and has demonstrated the safety and efficacy of its probiotic products in various disorders.

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)

_________________________________________________

www.biogaia.gr
www.facebook.com/Biogaia.Greece
www.instagram.com/biogaiagreece
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

Biogaia Protectis^® Junior

30x probiotic chewable tablets with lemon flavor

The world’s 1st probiotic in chewable tablets (2000)

Unique probiotic, with probiotic and prebiotic properties at the same time…by its nature!

For gasrtrointestinal health in children and adults

Gastrointestinal disorders caused by Antibiotics / Diarrhea / Constipation / Abdominal pain / Vomiting

FOR USE BY

Children from 3 years and adults

_________________________________________________

• It contains the world’s most studied probiotic strain in infants and children, one of the three most studied in adults
• Human strain, isolated in breast milk
• Natural habitat of our gastrointestinal tract from birth
• Unique parallel natural prebiotic action, due to its natural structure
• Clinically proven to colonize throughout the gastrointestinal tract
• Clinically proven per clinical benefit and age group
• Clinically proven, unique, natural, anti-pathogenic activity
• Safe for infants, children and adults, during pregnancy and breastfeeding and for diabetics
• Patented
• It contains no sugar, lactose, gluten, milk protein

• Scientifically documented in the prevention and treatment of functional gastrointestinal  disorders [(constipation/diarrhoea (regulates the bowel motility), reductions   (increases gastric emptying rate)]
• Clinically proven in the prevention and treatment of gastrointestinal disorders  associated with taking antibiotics (diarrhoea, abdominal pain, flatulence etc.)
• Clinically proven to improve digestive health and function, where 80% of our immune  system is located.
• Simple dosing regimen (1 tablet/day)

_________________________________________________

BioGaia Protectis^® probiotic chewable tablets are a simple, natural, safe and easy way to restore and maintain a healthy microbial balance in the gastrointestinal tract, as well as to improve digestive health and function.

BioGaia Protectis^® drops contain L. reuteri Protectis^® (L. reuteri DSM 17938), the patented probiotic bacterium of BioGaia Sweden. Originally isolated in breast milk, L. reuteri Protectis^® is the world’s most studied probiotic in infants and children and one of the three most studied in adults. Its safety and efficacy have been demonstrated in 217 clinical studies and 180 journal publications (last update: January 2020).

L. reuteri Protectis^® fully meets the requirements of WHO for probiotics. In an in vitro study comparing the viability of 35 different probiotic strains in a simulated human gastrointestinal tract over a period of five days, L. reuteri Protectis^® was shown to be one of the only three surviving strains. This was also confirmed in vivo, when ingestion from healthy humans led to significant colonisation of the stomach, duodenum and ileum.

L. reuteri Protectis^® colonizes the entire gastrointestinal tract, prevents the growth of harmful microorganisms, activates the immune system and improves gastrointestinal function.

In addition, it is the only probiotic that produces the antimicrobial substance rheuterine against pathogenic microorganisms.

It contains the unique probiotic strain Limosilactobacillus reuteri Protectis^®
(former name Lactobacillus reuteri Protectis^®).

The unique natural substance Limosi –a high molecular weight exopolysaccharide biofilm (EPS)– surrounding the probiotic strain L. reuteri Protectis® also acts as a prebiotic for the symbiotic flora.

This biofilm:

α)Protects the probiotic strain that surrounds it from

• other micro-organisms
• antibiotics
• toxic compounds
• osmotic stress

b) In human body 

• It inhibits the adhesion of pathogens to the intestinal epithelium
• It supports the symbiotic microflora, acting as a prebiotic (food)
• It regulates the immune system by activating T-regulatory cells and increasing anti-inflammatory cytokines

USE

GASTROINTESTINAL DISORDERS CAUSED BY ANTIBIOTICS
(diarrhoea, abdominal pain, flatulence)

PREVENTION & TREATMENT

DOSAGE (prevention)

1 tablet once daily between antibiotics + for 3 days afterwards

DOSAGE (treatment)

1 tablet once after each antibiotics administration + for 3 days after

_________________________________________________

FUNCTIONAL ABDOMINAL PAIN
(i.e. when there are no pathological causes)

TREATMENT

DOSAGE

1 tablet daily for at least 1 month

_________________________________________________

CHRONIC CONSTIPATION
(i.e. symptoms that persist for >2 weeks)

TREATMENT

DOSAGE

1 tablet once daily

_________________________________________________

BioGaia AB
_________________________________________________

BioGaia AB is a Swedish biotechnology company and a global leader in probiotics, with a strong innovation profile, experience and expertise of over 30 years. To date, BioGaia AB holds more than 550 patents, a commercial presence in more than 100 countries and a physical presence in Europe, USA, China and Japan. BioGaia’s vision is to improve people’s health by offering probiotic products that are clinically documented and proven for safety and efficacy by clinical benefit and age group. Until now (2/2020) BioGaia AB has completed more than 217 clinical studies in infants, children and adults and has demonstrated the safety and efficacy of its probiotic products in various disorders.

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)

_________________________________________________

www.biogaia.gr
www.facebook.com/Biogaia.Greece
www.instagram.com/biogiaiagreece
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

BioGaia Protectis^® Junior

10x probiotic chewable tablets with lemon flavor

The world’s 1st probiotic in chewable tablets (2000)

Unique probiotic, with probiotic and prebiotic properties at the same time…by its nature!

For gasrtrointestinal health in children and adults

Gastrointestinal disorders caused by Antibiotics / Diarrhoea / Constipation / Abdominal pain / Vomiting

FOR USE BY

Children from 3 years and adults

_________________________________________________

• It contains the world’s most studied probiotic strain in infants and children, one of the three most studied in adults
• Human strain, isolated in breast milk
• Natural habitat of our gastrointestinal tract from birth
• Unique parallel natural prebiotic action, due to its natural structure
• Clinically proven to colonize throughout the gastrointestinal tract
• Clinically proven per clinical benefit and age group
• Clinically proven, unique, natural, anti-pathogenic activity
• Safe for infants, children and adults, during pregnancy and breastfeeding and for diabetics
• Patented
• It contains no sugar, lactose, gluten, milk protein

• Scientifically documented in the prevention and treatment of functional gastrointestinal  disorders
  [(constipation/diarrhoea (regulates the bowel motility), reductions (increases gastric emptying rate)]
• Clinically proven in the prevention and treatment of gastrointestinal disorders  associated with taking antibiotics (diarrhoea, abdominal pain, flatulence etc.)
• Clinically proven to improve digestive health and function, where 80% of our immune  system is located.
• Simple dosing regimen (1 tablet/day)

_________________________________________________

BioGaia Protectis^® probiotic chewable tablets are a simple, natural, safe and easy way to restore and maintain a healthy microbial balance in the gastrointestinal tract, as well as to improve digestive health and function.

L.reuteri Protectis^® fully meets the requirements of WHO for probiotics. In an in vitro study comparing the viability of 35 different probiotic strains in a simulated human gastrointestinal tract over a period of five days, L. reuteri Protectis^® was shown to be one of the only three surviving strains. This was also confirmed in vivo, when ingestion from healthy humans led to significant colonisation of the stomach, duodenum and ileum.

L. reuteri Protectis^® colonizes the entire gastrointestinal tract, prevents the growth of harmful microorganisms, activates the immune system and improves gastrointestinal function.

In addition, it is the only probiotic that produces the antimicrobial substance rheuterine against pathogenic microorganisms.

It contains the unique probiotic strain Limosilactobacillus reuteri Protectis^®
(former name Lactobacillus reuteri Protectis^®).

The unique natural substance Limosi –a high molecular weight exopolysaccharide biofilm (EPS)– surrounding the probiotic strain L. reuteri Protectis® also acts as a prebiotic for the symbiotic flora.

This biofilm:

 α) Protects the probiotic strain that surrounds it from

• other micro-organisms
• antibiotics
• toxic compounds
• osmotic stress

b) In human body

• It inhibits the adhesion of pathogens to the intestinal epithelium
• It supports the symbiotic microflora, acting as a prebiotic (food)
• It regulates the immune system by activating T-regulatory cells andincreasing anti-inflammatory cytokines

USE

GASTROINTESTINAL DISORDERS CAUSED BY ANTIBIOTICS
(diarrhoea, abdominal pain, flatulence)

PREVENTION & TREATMENT

DOSAGE (prevention)

1 tablet once daily between antibiotics + for 3 days afterwards

DOSAGE (treatment)

1 tablet once after each antibiotics administration + for 3 days after

_________________________________________________

FUNCTIONAL ABDOMINAL PAIN
(i.e. when there are no pathological causes)

TREATMENT

DOSAGE

1 tablet daily for at least 1 month

_________________________________________________

CHRONIC CONSTIPATION
(i.e. symptoms that persist for >2 weeks)

TREATMENT

DOSAGE

1 tablet once daily

_________________________________________________

SUDDEN GASTROINTESTINAL DISORDERS
(diarrhoea, vomiting, flatulence, etc.)

TREATMENT

DOSAGE

2 tablets once daily

_________________________________________________

BioGaia AB

_________________________________________________

BioGaia AB is a Swedish biotechnology company and a global leader in probiotics, with a strong innovation profile, experience and expertise of over 30 years. To date, BioGaia AB holds more than 550 patents, a commercial presence in more than 100 countries and a physical presence in Europe, USA, China and Japan. BioGaia’s vision is to improve people’s health by offering probiotic products that are clinically documented and proven for safety and efficacy by clinical benefit and age group. Until now (2/2020) BioGaia AB has completed more than 217 clinical studies in infants, children and adults and has demonstrated the safety and efficacy of its probiotic products in various disorders.

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)

_________________________________________________

www.biogaia.gr
www.facebook.com/Biogaia.Greece
www.instagram.com/biogaiagreece
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

BioGaia Protectis^® + D3 Baby

5 ml of probiotic drops

The world’s 1st and No1 probiotic in drops (2004)

Unique probiotic, with probiotic and prebiotic properties at the same time…by its nature!

For infant colics and gastrointestinal health in infants and children

Gastrointestinal disorders caused by Antibiotics / Diarrhoea / Constipation / Abdominal pain / Vomit

With Vitamin D3: Proper immune function / Bone health / Prevention of rickets

FOR USE BY

Infants and toddlers

_________________________________________________

• The No1 probiotic worldwide for infant colic
• The only probiotic for infant colic with European and international recommendations*
• The only probiotic strain recommended for the treatment of colic in breastfeeding infants**
• Ability to prevent functional gastrointestinal disorders (infant colic,  constipation, reductions) in the first trimester of life***
• It contains the world’s most studied probiotic strain in infants and children, one of the three most studied in adults
• Human strain isolated in breast milk
• Natural colonizer of our gastrointestinal tract from birth
• With a unique parallel natural prebiotic action, due to its natural structure
• Clinically proven to colonize throughout the gastrointestinal tract
• Clinically proven per clinical benefit and age group
• Clinically proven, unique, natural anti-pathogenic activity
• Safe for infants, children and adults during pregnancy and breastfeeding   and for diabetics
• With vitamin D3, for proper immune function, bone health and prevention of rickets in infants and children
• Patented
• It contains no sugar, lactose, gluten, milk protein

* European Paediatric Association (Union of National Paediatric Societies and Associations,
EPA/UNEPSA), World Gastroenterology Organisation (WGO), Asia-Pacific Pediatric Gastroenterologists, Latin American Pediatric Gastroenterologists.
** Independent meta-analysis published in the journal Pediatrics by Sung (2018).
*** Independent study published in JAMA Pediatrics by Indrio (2014).

• Clinically proven to reduce colic in infants.
• Clinically proven in the prevention and treatment of functional  gastrointestinal disorders
  [(constipation/diarrhoea (regulates bowel motility),  reductions (increases the rate of gastric emptying)].
• Scientifically proven in the prevention and treatment of gastrointestinal disorders  associated with taking antibiotics (diarrhoea, abdominal pain, flatulence etc.).
• Scientifically proven to improve digestive health and function, where  80% of our immune  system is located.
• Easy to administer to infants and children.
• It does not affect breastfeeding or the taste of food.

_________________________________________________

BioGaia Protectis^® drops contain L. reuteri Protectis^® (L. reuteri DSM 17938), the patented probiotic bacterium of BioGaia Sweden. Originally isolated in breast milk, L. reuteri Protectis^® is the world’s most studied probiotic in infants and children and one of the three most studied in adults. Its safety and efficacy have been demonstrated in 217 clinical studies and 180 journal publications (last update: January 2020).

L. reuteri Protectis^® fully meets the requirements of WHO for probiotics. In an in vitro study comparing the viability of 35 different probiotic strains in a simulated human gastrointestinal tract over a period of five days, L. reuteri Protectis^® was shown to be one of the only three surviving strains. This was also confirmed in vivo, when ingestion from healthy humans led to significant colonisation of the stomach, duodenum and ileum.

L. reuteri Protectis^® colonizes the entire gastrointestinal tract, prevents the growth of harmful microorganisms, activates the immune system and improves gastrointestinal function.

In addition, it is the only probiotic that produces the antimicrobial substance rheuterine against pathogenic microorganisms.

+VITAMIN D

The recommended dosage of 5 drops per day provides 400 IU of vitamin D according to the European Food Safety Authority (EFSA) for infants and children. A daily intake of 400IU of vitamin D is recommended to meet the nutritional needs of vitamin D for proper bone development in infants and children and the prevention of rickets. Meeting these needs is often difficult due to the dependence of intake on each person’s diet, sun exposure, skin color and underlying diseases.

L. reuteri Protectis® has been shown to improve the body’s absorption of vitamin D and works synergistically to strengthen the immune system.

It contains the unique probiotic strain Limosilactobacillus reuteri Protectis^®
(former name Lactobacillus reuteri Protectis^®).

The unique natural substance Limosi –a high molecular weight exopolysaccharide biofilm (EPS)– surrounding the probiotic strain L. reuteri Protectis® also acts as a prebiotic for the symbiotic flora.

This biofilm:

a) Protects the probiotic strain that surrounds it from

• other micro-organisms
• antibiotics
• toxic compounds
• osmotic stress

b) In human body

• It inhibits the adhesion of pathogens to the intestinal epithelium.
• It supports the symbiotic microflora, acting as a prebiotic (food).
• It regulates the immune system by activating T-regulatory cells and increasing anti-inflammatory cytokines.

USE – GASTROINTESTINAL DISORDERS

COLICS OF THE 1ST TRIMESTER

PREVENTION & TREATMENT

DOSAGE

5 drops once daily

_________________________________________________ 

GASTROINTESTINAL DISORDERS CAUSED BY TAKING ANTIBIOTICS IN INFANTS AND YOUNG CHILDREN
(diarrhoea, abdominal pain, flatulence)

PREVENTION & TREATMENT

DOSAGE (prevention)

5 drops once daily, between antibiotics + for 3 days afterwards

DOSAGE (treatment)

5 drops once 1 hour after each antibiotics administration + for 3 days after

_________________________________________________

GASTROINTESTINAL DISORDERS IN INFANTS DURING THE FIRST 3 MONTHS OF LIFE
(colic, constipation, reductions)

PREVENTION & TREATMENT

DOSAGE

5 drops once daily for the first 3 months

_________________________________________________ 

SUDDEN GASTROINTESTINAL DISORDERS
(diarrhoea, vomiting, flatulence, etc.)

TREATMENT

DOSAGE

10 drops once daily

USE – IMMUNE SYSTEM

HYPOVITAMINOSIS D

PREVENTION & TREATMENT

DOSAGE (prevention)

5 drops once daily

DOSAGE (treatment)

10 drops once daily

_________________________________________________ 

BOOSTING THE IMMUNE SYSTEM

PREVENTION

DOSAGE

5 drops once daily

_________________________________________________ 

WEAKENED IMMUNE SYSTEM

TREATMENT

DOSAGE

10 drops once daily

_________________________________________________

BioGaia AB

_________________________________________________

BioGaia AB is a Swedish biotechnology company and a global leader in probiotics, with a strong innovation profile, experience and expertise of over 30 years. To date, BioGaia AB holds more than 550 patents, a commercial presence in more than 100 countries and a physical presence in Europe, USA, China and Japan. BioGaia’s vision is to improve people’s health by offering probiotic products that are clinically documented and proven for safety and efficacy by clinical benefit and age group. Until now (2/2020) BioGaia AB has completed more than 217 clinical studies in infants, children and adults and has demonstrated the safety and efficacy of its probiotic products in various disorders.

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)

_________________________________________________

www.biogaia.gr
www.facebook.com/Biogaia.Greece
www.instagram.com/biogaiagreece
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

BioGaia Protectis^® Baby

5 ml of probiotic drops

The world’s 1st and No1 probiotic in drops (2004)

Unique probiotic, with probiotic and prebiotic properties at the same time…by its nature!

For infant colics and gastrointestinal health in infants and children>

Gastrointestinal disorders caused by Antibiotics / Diarrhoea / Constipation / Abdominal pain / Vomit

FOR USE BY

Infants and toddlers

_________________________________________________

• The No1 probiotic worldwide for infant colic
• The only probiotic for infant colic with European and international recommendations*
• The only probiotic strain recommended for the treatment of colic in breastfeeding infants**
• Ability to prevent functional gastrointestinal disorders (infant colic, constipation, reductions) in the first trimester of life***
• It contains the world’s most studied probiotic strain in infants and children, one of the three most studied in adults
• Human strain isolated in breast milk
• Natural colonizer of our gastrointestinal tract from birth
• With a unique parallel natural prebiotic action, due to its natural structure
• Clinically proven to colonize throughout the gastrointestinal tract
• Clinically proven per clinical benefit and age group
• Clinically proven, unique, natural anti-pathogenic activity
• Safe for infants, children and adults during pregnancy and breastfeeding and for diabetics
• Patented
• It contains no sugar, lactose, gluten, milk protein

* European Paediatric Association (Union of National Paediatric Societies and Associations,
EPA/UNEPSA), World Gastroenterology Organisation (WGO), Asia-Pacific Pediatric Gastroenterologists, Latin American Pediatric Gastroenterologists.
** Independent meta-analysis published in the journal Pediatrics by Sung (2018).
*** Independent study published in JAMA Pediatrics by Indrio (2014).

• Clinically proven to reduce colic in infants.
• Clinically proven in the prevention and treatment of functional  gastrointestinal disorders
  [(constipation/diarrhoea (regulates bowel motility),  reductions (increases the rate of gastric emptying)].
• Scientifically proven in the prevention and treatment of gastrointestinal disorders  associated with taking antibiotics (diarrhoea, abdominal pain, flatulence etc.).
• Scientifically proven to improve digestive health and function, where  80% of our immune  system is located.
• Easy to administer to infants and children.
• It does not affect breastfeeding or the taste of food.

_________________________________________________

BioGaia Protectis^® drops contain L. reuteri Protectis^® (L. reuteri DSM 17938), the patented probiotic bacterium of BioGaia Sweden. Originally isolated in breast milk, L. reuteri Protectis^® is the world’s most studied probiotic in infants and children and one of the three most studied in adults. Its safety and efficacy have been demonstrated in 217 clinical studies and 180 journal publications (last update: January 2020).

L. reuteri Protectis^® fully meets the requirements of WHO for probiotics. In an in vitro study comparing the viability of 35 different probiotic strains in a simulated human gastrointestinal tract over a period of five days, L. reuteri Protectis^® was shown to be one of the only three surviving strains. This was also confirmed in vivo, when ingestion from healthy humans led to significant colonisation of the stomach, duodenum and ileum.

L. reuteri Protectis^® colonizes the entire gastrointestinal tract, prevents the growth of harmful microorganisms, activates the immune system and improves gastrointestinal function.

In addition, it is the only probiotic that produces the antimicrobial substance rheuterine against pathogenic microorganisms.

It contains the unique probiotic strain Limosilactobacillus reuteri Protectis^®
(former name Lactobacillus reuteri Protectis^®).

The unique natural substance Limosi –a high molecular weight exopolysaccharide biofilm (EPS)– surrounding the probiotic strain L. reuteri Protectis® also acts as a prebiotic for the symbiotic flora.

This biofilm:

a) Protects the probiotic strain that surrounds it from

• other micro-organisms
•  antibiotics
• toxic compounds
• osmotic stress

b) In human body

• It inhibits the adhesion of pathogens to the intestinal epithelium.
• It supports the symbiotic microflora, acting as a prebiotic (food).
• It regulates the immune system by activating T-regulatory cells and   increasing anti-inflammatory cytokines.

USE – GASTROINTESTINAL DISORDERS

COLICS OF THE 1ST TRIMESTER

PREVENTION & TREATMENT

DOSAGE

5 drops once daily

_________________________________________________

GASTROINTESTINAL DISORDERS CAUSED BY TAKING ANTIBIOTICS IN INFANTS AND YOUNG CHILDREN
(diarrhoea, abdominal pain, flatulence)

PREVENTION & TREATMENT

DOSAGE (prevention)

5 drops once daily, between antibiotics + for 3 days afterwards

DOSAGE (treatment)

5 drops once 1 hour after each antibiotics administration + for 3 days after

_________________________________________________

GASTROINTESTINAL DISORDERS IN INFANTS DURING THE FIRST 3 MONTHS OF LIFE
(colic, constipation, reductions)

PREVENTION & TREATMENT

DOSAGE

5 drops once daily for the first 3 months

_________________________________________________

SUDDEN GASTROINTESTINAL DISORDERS
(diarrhoea, vomiting, flatulence, etc.)

TREATMENT

DOSAGE

10 drops once daily

USE – IMMUNE SYSTEM

HYPOVITAMINOSIS D

PREVENTION & TREATMENT

DOSAGE (prevention)

5 drops once daily

DOSAGE (treatment)

10 drops once daily

_________________________________________________

BOOSTING THE IMMUNE SYSTEM

PREVENTION

DOSAGE

5 drops once daily

_________________________________________________

WEAKENED IMMUNE SYSTEM

TREATMENT

DOSAGE

10 drops once daily

_________________________________________________

BioGaia AB
_________________________________________________

BioGaia AB is a Swedish biotechnology company and a global leader in probiotics, with a strong innovation profile, experience and expertise of over 30 years. To date, BioGaia AB holds more than 550 patents, a commercial presence in more than 100 countries and a physical presence in Europe, USA, China and Japan. BioGaia’s vision is to improve people’s health by offering probiotic products that are clinically documented and proven for safety and efficacy by clinical benefit and age group. Until now (2/2020) BioGaia AB has completed more than 217 clinical studies in infants, children and adults and has demonstrated the safety and efficacy of its probiotic products in various disorders.

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)

_________________________________________________

www.biogaia.gr
www.facebook.com/Biogaia.Greece
www.instagram.com/biogaiagreece
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

Capricare^®  1 Γάλα 2ης βρεφικής ηλικίας

400gr

The Original (1988) and No1 goat milk infant formula worldwide

Based on WHOLE goat milk

The only goat milk for infants evaluated by EFSA

FOR USE BY

Infants from 6 to 12 months

_________________________________________________

• The ORIGINAL goat milk infant formula (1988)
• The world’s No1 goat milk infant formula
• It is made from whole goat milk
• The only goat milk formula for infants that is clinically evaluated by the European Food Safety Agency (EFSA) for the proper development of a healthy infant
• The most studied goat milk infant formula
• Produced in the world’s most advanced, state of the art, manufacturing  facility for production of goat milk infant formulas, designed to produce only infant formula exclusively from goat milk
• Unique vertical production (from breeding and milking to the final product)
• It complies with the European Directive for infant milk
• Enriched with long-chain polyunsaturated fatty acids (AA and DHA)

_________________________________________________

Milk powder for the 2nd infant age of infants from the 6th to the 12th month and for the weaning period. It is prepared with whole goat milk as raw material instead of mixing ingredients, resulting in the mildest possible processing.

It complies with the European Infant Formula Directive and it is the only one clinically evaluated by the European Food Safety Agency (EFSA).

It is produced by the world leader in research, development and production of whole goat milk for infants, Dairy Goat Co-operative (DGC) New Zealand.

DGC’s unique and vertically integrated production process (breeding – milking – milk powder production – manufacturing of packaging materials – canning) ensures:

FASTEST PROCESS POSSIBLE

From milking the goats to milk powder within couple of days. It ensures the freshness and natural properties of whole goat milk.

LESS HARM TO THE RAW MATERIAL

The mildest heat treatment, with the least possible “disturbance” of the proteins and the lowest percentage of glycosylated compounds in the final product.

REDUCED RISK OF CONTAMINATION

No long-term storage of ingredients, large number of suppliers, transport and processing in other factories or countries.

QUALITY ASSURANCE

30 years of expertise. 100% focus on exclusive production of infant milk from whole goat milk. Total control of raw materials, packaging materials and all stages of production, ensuring the quality of the final product.

RESULT

The benefits of the unique natural properties of whole goat milk are retained in the final product:

• Better digestibility, due to its protein and lipid profile and milder processing
• Lower antigenicity
• Preservation of the liposphere membrane and the natural content of bioactive substances,   such as prebiotic oligosaccharides, nucleotides, amino acids, etc.

_________________________________________________

DAIRY GOAT CO-OPERATIVE (DGC)

_________________________________________________

Dairy Goat Co-operative (DGC) Ltd., Nea Zealand, is the world leader in infant milk from goat milk. DGC is the inventor of infant milk from goat milk (1988). Throughout these 30 years, DGC has managed to keep a continuous evolution and to develop a highly sophisticated model of expertise around infant milk based on goat milk, that lead to the change of the European legislation for infant milks in 2012. DGC is a highly integrated co-operation, where every step in infant milk production, from farming and milking to infant milk in the can, is handled, controlled and completed in whole by DGC. The final product is produced and packaged in the world’s most sophisticated production facility for infant milk, designed to produce exclusively infant milk from whole goat milk.

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)
_________________________________________________

www.capricare.gr
www.facebook.com/Capricare.Greece
www.instagram.com/capricaregreece
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

Capricare^®  2 Γάλα 2ης βρεφικής ηλικίας

400gr

The Original (1988) and No1 goat milk infant formula worldwide

Based on WHOLE goat milk

The only goat milk for infants evaluated by EFSA

FOR USE BY

Infants from 6 to 12 months

_________________________________________________

• The ORIGINAL goat milk infant formula (1988)
• The world’s No1 goat milk infant formula
• It is made from whole goat milk
• The only goat milk formula for infants that is clinically evaluated by the European Food Safety Agency (EFSA) for the proper development of a healthy infant
• The most studied goat milk infant formula
• Produced in the world’s most advanced, state of the art, manufacturing  facility for production of goat milk infant formulas, designed to produce only infant formula exclusively from goat milk
• Unique vertical production (from breeding and milking to the final product)
• It complies with the European Directive for infant milk
• Enriched with long-chain polyunsaturated fatty acids (AA and DHA)

_________________________________________________

Milk powder for the 2nd infant age of infants from the 6th to the 12th month and for the weaning period. It is prepared with whole goat milk as raw material instead of mixing ingredients, resulting in the mildest possible processing.

It complies with the European Infant Formula Directive and it is the only one clinically evaluated by the European Food Safety Agency (EFSA).

It is produced by the world leader in research, development and production of whole goat milk for infants, Dairy Goat Co-operative (DGC) New Zealand.

DGC’s unique and vertically integrated production process (breeding – milking – milk powder production – manufacturing of packaging materials – canning) ensures:

FASTEST PROCESS POSSIBLE

From milking the goats to milk powder within couple of days. It ensures the freshness and natural properties of whole goat milk.

LESS HARM TO THE RAW MATERIAL

The mildest heat treatment, with the least possible “disturbance” of the proteins and the lowest percentage of glycosylated compounds in the final product.

REDUCED RISK OF CONTAMINATION

No long-term storage of ingredients, large number of suppliers, transport and processing in other factories or countries.

QUALITY ASSURANCE

30 years of expertise. 100% focus on exclusive production of infant milk from whole goat milk. Total control of raw materials, packaging materials and all stages of production, ensuring the quality of the final product.

RESULT

The benefits of the unique natural properties of whole goat milk are retained in the final product:

• Better digestibility, due to its protein and lipid profile and milder processing
• Lower antigenicity
• Preservation of the liposphere membrane and the natural content of bioactive substances,   such as prebiotic oligosaccharides, nucleotides, amino acids, etc.

_________________________________________________

DAIRY GOAT CO-OPERATIVE (DGC)

_________________________________________________

Dairy Goat Co-operative (DGC) Ltd., Nea Zealand, is the world leader in infant milk from goat milk. DGC is the inventor of infant milk from goat milk (1988). Throughout these 30 years, DGC has managed to keep a continuous evolution and to develop a highly sophisticated model of expertise around infant milk based on goat milk, that lead to the change of the European legislation for infant milks in 2012. DGC is a highly integrated co-operation, where every step in infant milk production, from farming and milking to infant milk in the can, is handled, controlled and completed in whole by DGC. The final product is produced and packaged in the world’s most sophisticated production facility for infant milk, designed to produce exclusively infant milk from whole goat milk.

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)
_________________________________________________

www.capricare.gr
www.facebook.com/Capricare.Greece
www.instagram.com/capricaregreece
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma

Lacteeze® chewable tablets

10x chewable tablets with natural strawberry flavor

Natural lactase enzyme

For the breakdown of lactose before the consumption of solid and liquid foods and products containing lactose [e.g. yoghurt, cheese, biscuits etc. or fresh milk, powdered milk, condensed milk, breast milk, formula, chocolate milk, etc.]

FOR USE BY

Newborn infants (dissolved in milk, water, etc.), children and adults

_________________________________________________

• Not a drug – it is a natural enzyme that under normal conditions is prodcuced in the digestive tract
• It breaks down the lactose in milk, it can be consumed without the occurrence of the unwanted
• symptoms caused by lactose intolerance
• Safe from birth
• Safe during pregnancy and breastfeeding
• Does not contain preservatives, artificial colours or flavorings
• Clinically proven action
• Allows children and adults to continue drinking milk (e.g. fresh, extensively pasteurized, chocolate flavored etc.)
• Enables mothers to continue breastfeeding, even if their baby has lactose intolerance
• Does not contain gluten, dairy elements

_________________________________________________

LACTASE ENZYME

_________________________________________________

The enzyme lactase is naturally produced in the small intestine and it is responsible for breaking down lactose in foods containing it (dairy and products containing lactose) to enable its absorption by our body. As we grow older, the body’s production of lactase gradually decreases. The inhibition of its production also occurs after gastroenteritis, where the intestine is “injured” and it takes 1–2 weeks to return to its normal function in terms of enzyme production. Therefore, after gastroenteritis, Lacteeze^® can help to continue consuming milk without problems.

Lacteeze^® chewable tablets are a simple, natural, safe and easy way for our body to obtain the natural enzyme lactase, which is deficient when we are lactose intolerant. It has been estimated that in Greece ≈30% of children and ≈70% of adults suffer from lactose intolerance. Most often, symptoms are attributed to other causes, due to possible misdiagnosis. If you frequently suffer from bloating, gas or flatulence, abdominal pain or watery stools, you may have lactose intolerance. Lacteeze^® restores nutritional completeness and taste satisfaction to those who avoid lactose-containing foods.

NOTE

Lacteeze^® is not absorbed. Whatever amount does not interact with the lactose consumed through dairy products is eliminated from the organism naturally. Lacteeze^® tablets should be taken every time you consume dairy products, just before consumption. Repeat the dose if dairy consumption continues after one hour. Adjust according to your needs. Take up to 3 times a day and no more than 12 tablets in total.

USE

BREASTFEEDING

Dissolve 1/4 of the tablet in a small amount of water or breast milk that you have extracted naturally or with a breast pump. Mix and give the mixture to the baby before you start breastfeeding

INFANT MILK

Dissolve 1/4 of the tablet in a small amount of water, milk that you have prepared. Mix and give the mixture to the baby before you start feeding

CHILDREN 2–3 YEARS

Do not give the tablet to children to swallow, there is a risk of choking. Dissolve 1 tablet in water or food just before eating dairy products

CHILDREN 4–12 YEARS

Chew 1 tablet just before consuming dairy products

ADULTS

Chew or swallow 1-3 tablets just before eating dairy products

_________________________________________________

PRODUCT NOTIFIED TO THE NATIONAL ORGANIZATION FOR MEDICINES (ΕΟΦ)

_________________________________________________

www.lacteeze.eu
www.cube-pharmaceuticals.gr
www.facebook.com/Cube.Pharma
www.instagram.com/cubepharma